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Abstract

CHARACTERIZATION OF THE EFFECT OF SERUM AND CHELATING AGENTS
ON STAPHYLOCOCCUS AUREUS BIOFILM FORMATION; CHELATING AGENTS
AUGMENT BIOFILM FORMATION THROUGH CLUMPING FACTOR B
By: Nabil Mathew Abraham, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Kimberly Jefferson, Ph.D.
Associate Professor, Department of Microbiology and Immunology

Staphylococcus aureus is the causative agent of a diverse array of acute and
chronic infections, and some these infections, including infective endocarditis, joint
infections, and medical device-associated bloodstream infections, depend upon its
capacity to form tenacious biofilms on surfaces. Inserted medical devices such as
intravenous catheters, pacemakers, and artificial heart valves save lives, but
unfortunately, they can also serve as a substrate on which S. aureus can form a biofilm,
attributing S. aureus as a leading cause of medical device-related infections. The major
aim of this work was take compounds to which S. aureus would be exposed during
xvi

infection and to investigate their effects on its capacity to form a biofilm. More
specifically, the project investigated the effects of serum, and thereafter of catheter lock
solutions on biofilm formation by S. aureus.
Pre-coating polystyrene with serum is frequently used as a method to augment
biofilm formation. The effect of pre-coating with serum is due to the deposition of
extracellular matrix components onto the polystyrene, which are then recognized by
MSCRAMMs. We therefore hypothesized that the major component of blood, serum,
would induce biofilm formation. Surprisingly, serum actually inhibited biofilm
formation. The inhibitory activity was due to a small molecular weight, heat-stable, nonproteinaceous component/s of serum. Serum-mediated inhibition of biofilm formation
may represent a previously uncharacterized aspect of host innate immunity that targets
the expression of a key bacterial virulence factor: the ability to establish a resistant
biofilm.
Metal ion chelators like sodium citrate are frequently chosen to lock intravenous catheters
because they are regarded as potent inhibitors of bacterial biofilm formation and viability.
We found that, while chelating compounds abolished biofilm formation in most strains of
S. aureus, they actually augmented the phenotype in a subset of strains. We investigated
the molecular basis of this phenomenon. Deletion and complementation analysis and
thereafter antibody based inhibition assays confirmed a functional role for the surface
adhesin clumping factor B as the causative determinant associated with the increased
biofilm phenotype. Finally, we investigated the regulation of clumping factor B-mediated
biofilm formation and the basis for the strain dependence. Regulation was determined to
xvii

occur via two novel post-translational networks- one affecting ClfB activity, mediated by
Ca2+ binding to the EF-Hand domain, and the other affecting protein stability, mediated
by the enzymatic activity of the metalloprotease-aureolysin. Polymorphisms within the
aureolysin gene sequence, between strains, was identified as the basis for some strains
forming robust biofilms within chelated media versus other than do not exhibit this
phenotype.

xviii

CHAPTER 1
Introduction

Clinical overview of Staphylococcus aureus
The staphylococci make up a family of Gram-positive cocci, Staphylococcaceae,
which is in the order Bacillales. The staphylococcal bacteria are named for their distinct
grape-like clustering morphology with the etiological root of the word "staphylococcus"
coming from the Greek word staphyle, meaning bunches of grapes. The staphylococci are
non-motile, non-spore forming facultative anaerobes that grow by aerobic respiration or
fermentation. Members of this genus are catalase positive and oxidase negative,
distinguishing them from the genus Streptococcus, which are catalase negative. To date,
there are 32 species and eight sub-species in the genus Staphylococcus (Kloos and
Bannerman, 1994); however, Staphylococcus aureus and S. epidermidis are the two bestcharacterized and studied strains. Pathogenic staphylococci are commonly identified by
their ability to produce coagulase, and thus clot serum (Kloos and Musselwhite, 1975).
This distinguishes the coagulase positive strains including S. aureus (primarily a human
pathogen) and S. intermedius and S. hyicus (two animal pathogens), from the other
staphylococcal species such as S. epidermidis, which are coagulase negative (CoNS).
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S. aureus is considered a major pathogen that colonizes and infects both
hospitalized patients with decreased immunity, and healthy immunocompetent
individuals within the community. While S. aureus is an important human pathogen, the
bacterium is typically found as a commensal. The human anterior nare is the main
reservoir with approximately 20% of individuals persistently colonized with S. aureus
and 30% intermittently colonized (Wertheim, Melles et al., 2005; Kluytmans, van
Belkum et al., 1997; Cole, Tahk et al., 2001). However, numerous other sites may be
colonized, including the axillae, groin, and gastrointestinal tract. Colonization increases
the risk for subsequent infection since it provides a reservoir from which bacteria can be
introduced when host defenses are breached, e.g. by shaving, aspiration, insertion of an
indwelling catheter or by surgery. von Eiff et al. provided empirical evidence to this in a
study of bacteremia, where blood isolates were identical to nasal isolates in 82% of
patients (von Eiff, Becker et al., 2001).
Once S. aureus crosses the epithelial boundary, the opportunistic nature of this
pathogen, compounded with the armamentarium of virulence factors, facilitates it to
infect a wide variety of body tissue. These infections vary in severity from minor,
generally self-limiting, purulent soft-tissue skin infections including folliculitis, impetigo
and carbuncles (boils) to a variety of life-threatening, potentially fatal, infections
including necrotizing pneumonia, osteomyelitis, infective endocarditis and bacteremia. S.
aureus is the most common cause of bloodstream, skin and soft tissue, and nosocomial
lower respiratory tract infections in the United States and Canada (Diekema, Pfaller et al.
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2001). The economic impact on the U.S. healthcare system from S. aureus infections is
$14.5 billion annually (Noskin, Rubin et al., 2007).
S. aureus is also the leading cause of hospital-associated infections in the United
States (Styers, Sheehan et al., 2006). This is a direct corollary with the organisms’ ability
to become multi-drug resistant. With the emergence of antibiotic resistant strains of S.
aureus, including, Methicillin-resistant Staphylococcus aureus or MRSA, control of such
infections has become a paramount clinical and pharmacologic battle (Bamberger and
Boyd 2005; Grundmann, Aires-de-Sousa et al., 2006). There are nearly 300,000 cases of
S. aureus infections in hospitalized patents each year in the U.S. Of these, roughly 43%
are related to MRSA (Kuehnert, Hill et al., 2005). The prevalence of MRSA infections in
hospitals has been increasing from 2% of all staphylococcal intensive care unit infections
in 1974, to 22% in 1995 and 64% in 2004 (Kuehnert, Kruszon-Moran et al., 2006). Until
recently, MRSA was thought to be a significant threat only in the hospital setting;
however, it has been shown that normal healthy individuals can become infected with
community acquired MRSA (CA-MRSA); thought to have evolved separately from the
hospital acquired clones (Voyich, Otto et al., 2006; Moroney, Heller et al., 2007;
Tenover, McDougal et al., 2006). The prevalence of MRSA has also been documented
within livestock. A report examining the prevalence of MRSA carriage in swine and
swine farmers in the Midwestern U.S. showed that the carriage rate for the animals on
average was roughly 50%. It was also found that 45% of the human workers tested
positive for MRSA colonization (Smith, Male et al., 2008). These numbers provide
evidence for the large threat that S. aureus poses as a significant human pathogen,
3

especially its antibiotic resistant derivative, MRSA.
Two antibiotics currently in circulation to treat MRSA are vancomycin and
daptomycin (Chambers and Deleo, 2009; Appleman and Citron, 2010). Vancomycin is a
glycopeptide antibiotic that acts to inhibit cell wall synthesis in Gram-positive bacteria
The large hydrophilic molecule forms hydrogen bond interactions with the terminal Dalanyl-D-alanine moieties of the N-acetylglucosamine (NAG)/ N-acetylmuramic acid
(NAM)-peptides. This binding of vancomycin to the D-Ala-D-Ala prevents cell wall
synthesis prevents the synthesis of the long polymers of NAM and NAG that form the
backbone strands of the bacterial cell wall, and it prevents the backbone polymers that do
manage to form from cross-linking with each other. Daptomycin, on the other hand
differs from vancomycin and has a distinct mechanism of action by binding to the
membrane causing rapid depolarization, resulting in a loss of membrane potential leading
to inhibition of protein, DNA and RNA synthesis, which results in bacterial cell death
Although these second line antibiotics are used sparingly so as not to promote the spread
of resistant strains, in 2002, the first vancomycin resistant S. aureus (VRSA) infection
was documented in a patient in the U.S. (Sievert, Boulton et al., 2002). This strain was
shown to carry the van gene cassette, suggesting that the resistance determinant might
have been acquired through the genetic exchange of material between vancomycin
resistant enterococci and S. aureus. The spread of vancomycin resistance worldwide is
inevitable and raises fears of a return to pre-antibiotic era. Hence, the need to identify
novel virulence-based bacterial targets is a critical pre-requisite in the search for new
antibiotics and prophylaxis strategies.
4

Catheter-related infections and Catheter Lock Solutions (CLS)
Primary bloodstream infections (BSIs) are the most common cause of morbidity
and mortality in hospitalized patients and are attributed to the increased use of
intravascular devices. It is estimated that there are over 400,000 catheter-related
nosocomial BSIs that occur annually in the United States (Maki, Kluger et al., 2006;
Raad and Hanna, 2002; Ramos, Reitzel et al., 2010). These infections account for 1020% of all nosocomial infections; they increase health care costs, prolong patient stay and
increase mortality rates (Hugonnet, Sax et al., 2004). These infections add $33,000$65,000 per case to healthcare costs with a yearly impact in the U.S. estimated to be $1.8
billion (Orsi, Di Stefano et al., 2002; Mayor, 2000). Most central venous catheter (CVC)related BSIs occur in patients in intensive care units (ICUs), followed by patients with
long-term catheters placed for cancer and hemodialysis. A recent study by Warren and
colleagues identified vascular device associated infections increased ICU length of stay
by 2.41 days and hospital length of stay by 7.54 days (Warren, Quadir et al., 2006). The
crude mortality rate of patients with CVC-related BSIs ranges from 12-35% (Pittet,
Tarara et al., 1994; Dimick, Pelz et al., 2001; Rello Ochagavia et al., 2000).
Staphylococci are the most common cause of CVC-related BSIs. While CoNS S.
epidermidis is a more frequent isolate, S. aureus, which accounts for 20% of BSIs, is
associated with higher morbidity and mortality due to severe hematogenous
complications, systemic sepsis and invasive infections such as endocarditis (Walz,
Memtsoudis et al., 2010). S. aureus catheter-related BSIs are associated with greater
health-related costs than any other isolated species (Walz, Memtsoudis et al., 2010) and
5

such infections result in a 6-fold increase in mortality rate in hospitalized patients
(Berger, Diab-Elschahawi et al., 2010).
With short-term intravascular catheters, such as peripheral IVs, bacterial
colonization and, in turn, contamination is most likely to result from skin microorganisms
(75-90%) (Sherertz, 2005; Sherertz, 2000). Such contamination often occurs on the
extraluminal surface of the catheter. These catheters can often be removed and replaced,
which, along with antibiotic therapy, results in resolution of the infection. However, longterm catheters like CVC often become contaminated intraluminally through contaminated
catheter hubs (66%) or by the skin commensals (26%). Several studies have
demonstrated that clinical findings correlate well with quantitative catheter cultures and
that, the higher number of microorganisms isolated from the surface of the catheter, the
greater likelihood of insertion site erythema and/or catheter-related BSIs (Sherertz, Raad
et al., 1990; Cleri, Corrado et al., 1980; Brun-Buisson, Abrouk et al., 1987; Siegman-Igra,
Anglim et al., 1997). Thus, removal and replacement of such devices is often complicated
(Crnich and Maki, 2002).
Factors affecting catheter colonization and infection can be divided into three major
categories: those that relate to the host (i.e. immunosuppression, staphylococcal
colonization of the nose, severity of underlying disease), the catheter (including duration
of catheterization, site of insertion catheter composition and antimicrobial coating), and
the causative microorganism. Microbial adherence to a biomaterial is an early, essential
event in the pathogenesis of a prosthetic device infection. Microbial risk factors that
mediate catheter colonization, as it pertains to S. aureus, include surface-associated
6

MSCRAMMs (Microbial surface components recognizing adhesive matrix molecules),
biofilm formation, and a variant subpopulation of S. aureus that grow slowly called
small-colony variants. These microbial factors aid in the initial stages of adherence and
biofilm formation and persistence towards infection. Adhesion and aggregation are
mediated by specific adhesin-receptor interactions. S. aureus adheres to host proteins
including fibrinogen, fibronectin, fibrin, collagen, bone sialoprotein, laminin, elastin, and
extracellular matrix proteins commonly found on intravascular devices (Herrmann,
Vaudaux et al., 1988). Exopolysaccharides like PNAG (poly-N-acetylglucosamine)
promote biofilm maturation and some studies suggest that it contributes to virulence
(Arciola, Baldassarri et al., 2001; Peacock, Moore et al., 2002; Peacock, de Silva et al.,
2002).
Recent guidelines for the prevention and treatment of catheter-related BSIs have
proposed the use of intraluminal antimicrobial lock solutions (Mermel, Farr et al., 2001;
O’Grady, Alexander et al., 2002; Raad, Costerton et al., 1993). During interdialytic
periods, the catheter lumen is locked with an anti-coagulant to prevent intraluminal
thrombosis. Some of these Catheter Lock Solutions (CLS), contain cationic chelators like
tri-sodium citrate (NaCi), ethylenediaminetetraacetic acid (EDTA), ethylene glycol-bis(2aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), which serve as effective anticoagulants and have recently been shown to possess added antimicrobial and antibiofilm
properties (Banin, Brady et al., 2006; Percival, Kite et al., 2005; Shanks, Sargent et al.,
2006). As shown in Figure 1, the antimicrobial activity of these cationic chelators stems
from several mechanistic activities. First, metallic cations are necessary for prokaryotic
7

Figure 1. The role of chelators in inhibiting bacterial growth, disrupting surface
adherence, and preventing biofilm formation. Chelators play an important role in
inhibiting biofilm formation through their capabilities of chelating metallic cations that
are vital in bacterial cell growth and microbial adherence to fibrin and biofilm formation.
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division and the integrity of the bacterial cell wall. EDTA, EGTA and NaCi chelate
metallic cations like calcium (Ca2+) and magnesium (Mg2+) leading to inhibition of
bacterial growth. Secondly, Ca2+ chelators inhibit the formation of fibrin, which plays an
important role in adherence of microbial organisms to the surface of an indwelling
catheter. Additionally, these divalent cations can stimulate cell-cell adhesion and thus
promote aggregation through the shared binding of divalent cations by cell wall teichoic
acids; this increases the number of organisms adhering to a finite surface area (Dunne and
Burd, 1992; Hall-Stoodley, Costerton et al., 2004). The third mechanism relates to the
negative effect chelators have on biofilm formation; this property has been utilized in
treating biofilm-related infections by several research groups (Banin, Brady et al., 2006;
Raad, Chatzinikolaou et al., 2003; Percival, Kite et al., 2005). In S. aureus, sub-inhibitory
doses of chelators prevent biofilm formation, at least in part by targeting PNAG (Juda,
Paprota et al., 2008; Ozerdem Akpolat, Elci et al., 2003; Shanks, Sargent et al., 2006;
Weijmer, Debets-Ossenkopp et al., 2002). While a very low level of NaCi has been
shown to augment S. aureus biofilm formation, seemingly by acting as a TCA cycle
intermediate within the bacterial cell, concentrations of NaCi ≥ 0.5% effectively inhibit
the biofilm phenotype (Shanks, Meehl et al., 2008; Shanks, Sargent et al., 2006).
Therefore many CLS, such as Citra-Lock ™, Dura-Lock-C ™, and Loxxit ™, are now
composed solely of the chelating agent tri-sodium citrate.

Staphylococcus aureus virulence and regulation
Genome sequencing of the staphylococci has provided unprecedented insight into
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their success as significant bacterial pathogens. Within the past decade, genomes of 13 S.
aureus, two S. epidermidis, one S. haemolyticus, and one S. saprophyticus have been
sequenced (Baba, Bae et al., 2008; Baba, Takeuchi et al., 2002; Diep, Gill et al., 2006;
Gill, Fouts et al., 2005; Herron-Olson, Fitzgerald et al., 2007; Holden, Feil et al., 2004;
Kuroda, Ohta et al., 2001; Kuroda, Yamashita et al., 2005; Taeuchi, Watanabe et al.,
2005). The first sequenced S. aureus genomes were published in 2001 by the Hiramatsu
group comparing two methicillin-resistant strains, N315 and Mu50 (Kuroda, Ohta et al.,
2001). These genome sequences were followed in quick succession over the next 7 years
by publication of the genome sequences of MW2 (Baba, Takeuchi et al., 2002),
MRSA252 and MSSA476 (Holden, Feil et al., 2004), COL (Gill, Fouts et al., 2005),
USA300-FPR3737 (Diep, Gill et al., 2006), USA300-HOU-MR (Highlander, Hulten et
al., 2007), NCTC8325 (Gillaspy, Worrell et al., 2006), ET3-1 (Herron-Olson, Fitzgerald
et al., 2007), JH1 and JH9 (Mwangi, Wu et al., 2007) and, most recently, Newman (Baba,
Bae et al., 2008). Comparative genome analyses between the sequenced strains have
identified close evolutionary relationships; analyses have revealed the presence of not
only core metabolic functions shared by all S. aureus strains, but also previously
unidentified virulence factors with key roles in pathogenesis. The arsenal of virulence
factors of S. aureus is extensive with both structural and secreted products playing a role
in the pathogenesis of infections.
Biofilms
Many pathogenic and commensal bacteria are capable of transitioning between
life in the environment and in the human host, and all must be able to adapt to sudden
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shifts in nutrient availability as well as primary and secondary host immune defenses.
One particularly important and clinically relevant example of bacterial adaptation through
systematized gene expression is the ability to grow as part of a sessile, exoploymerenshrouded community referred to as a biofilm. A biofilm is an adherent community of
bacteria with an organized structure and chemistry, surrounded by an extracellular
biochemical polymer. Scientific interest in the process of biofilm formation has erupted
in recent years since this mode of growth has been recognized as distinct from its
planktonic or free-floating counterpart and vital for bacterial growth in nature or in
infectious diseases (O’Toole, Kaplan et al., 2000; Lindsay and van Holy, 2006).
Biofilm formation is an important aspect of many, if not most bacterial diseases
including native valve endocarditis, osteomyelitis, dental caries, middle ear infections,
medical device-related infections, ocular implant infections and chronic lung infections in
cystic fibrosis patients (Donlan and Costerton, 2002). Biofilms impart numerous
advantages to their resident bacteria that would encourage this mode of growth. Biofilms
impart, on its constituent bacteria, resistance to antimicrobial agents (Passerini de Rossi,
Garcia et al. 2009), disinfectants (Kim, Ryu et al. 2007), drying (Vanderlinde, Harrison et
al. 2009), ultraviolet light (Bak, Ladefoged et al. 2009), acid exposure (Kubota, Senda et
al. 2009), phagocytosis (Cerca, Jefferson et al. 2006) and sheer stress (Giao, Azevedo et
al. 2008). Increased resistance to antimicrobials and immune defenses frequently makes
biofilm-related infections chronic and/or recurrent. In addition, the physiological
heterogeneity throughout the biofilm results in a form of “division of labor”, which
endows the community with a higher metabolic potential than an equivalent planktonic
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population increasing their overall fitness. While both S. aureus and CoNS S. epidermidis
can form biofilms, S. aureus harbors more virulence factors and is therefore associated
with more severe disease manifestations (George and Muir, 2007). The serious and
pervasive clinical impact of S. aureus biofilms has inspired focused research and study of
this developmental process with the ultimate goal of pinpointing targets for
chemotherapeutic agents.
As with any developmental process, biofilm formation is associated with a series
of complex but distinct and well-regulated steps. While the exact molecular mechanisms
differ from organism to organism, transitioning from a planktonic to a biofilm state, the
stages are similar across a wide range of microorganisms. Described schematically in
Figure 2, the steps associated with this process can be arbitrarily divided into five stages:
(i) initial attachment, (ii) irreversible attachment mediated by bacterial surface adhesins,
(iii) aggregation through the expression of intracellular adhesins, (iv) maturation and
development of biofilm architecture, and (v) dispersion of cells from the biofilm
(Stoodley, Sauer et al., 2002). Certain stressors including temperature, osmolarity shock,
low oxygen tension, changes in the availability of glucose, glucosamine and Nacetylglucosamine, changes in cyclic-di-GMP levels, and exposure to toxic chemicals
such as ethanol and antibiotics can induce global changes in gene expression initiating
the switch to a sessile biofilm growth modality (Shanks, Donegan et al., 2005; Cramton,
Ulrich et al., 2001; Lim, Jana et al., 2004; Resch, Rosenstein et al., 2005; Beenken,
Dunman et al., 2004).
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Figure 2. Schematic representation of the stages of biofilm formation in
Staphylococcus aureus. Biofilm formation by S. aureus can be divided into five stages.
(i) Initial attachment: Cells make their first points of contact with their substratum of
choice. These interactions are mediated primarily via non-specific charge interactions and
cell surface hydrophobicity. (ii) Irreversible attachment: A stronger, more intimate
contact is made between the cells and their surface. Adhesion to host extracellular matrix
components is propagated by various surface-associated and secreted adhesins. (iii)
Aggregation: After adhesion to the surface, microcolony formation occurs promoted by
surface proteins including biofilm-associated protein (Bap), S. aureus surface protein G
(SasG), and accumulation/adhesion-associated protein (Aap). Exopolysaccharide
production (PNAG) along with accessory macromolecules, such as teichoic acids, aid
intracellular aggregation. (iv) Maturation: Cell communication (potentially through the
agr quorum sensing system) leads to cell clusters reaching maximum thickness via
production of copious amounts of exopolysaccharide (PNAG). Cells lysis occurs
releasing eDNA. (v) Dispersion: Release of bacteria from the biofilm architecture
through shearing or production of exoenzymes (alginate lyase in P. aeruginosa) to return
to a planktonic lifestyle or to seed another location for biofilm formation.
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In the initial stage of biofilm formation, bacteria reversibly adhere to a solid
surface via nonspecific charge-related interactions and hydrophobic interactions between
the cells and their substratum of choice. This is quickly followed by the second stage
wherein the bacteria irreversibly attach to the surface. This step is critical in the
pathogenesis of all bacterial infections since the bacteria must adhere to the host tissue to
avoid clearance by host defenses that physically remove non-self entities, such as the
mucociliary escalator. S. aureus produces numerous proteinaceous adhesins called
MSCRAMMs, which by definition, are surface associated proteins that specifically bind
to some component of the host extracellular matrix (Foster and Hook, 1998). The
formation of a biofilm on the surface of a subvenous catheter has been extensively
researched. When inserting a catheter into the bloodstream, bacteria can become attached
to the tip and length of the catheter surface. Rapidly, blood plasma proteins, platelets,
fibrin and leukocytes bind to the surface of the catheter; these host products serve as
scaffolding for the developing biofilm and receptors for newly arriving bacteria
(Cappelli, Tetta et al. 2005). S. aureus tightly adheres to proteins like fibrinogen and
fibronectin that coat the surface of the catheter using their MSCRAMM proteins thereby
promoting irreversible attachment (Arciola, Campoccia et al. 2005; O'Neill, Humphreys
et al. 2009).
The third stage of biofilm formation distinguishes adherent bacteria from bacteria
that establish themselves within a biofilm. At this stage, the staphylococci initiate
expression of intercellular adhesins that allow the bacterial cells to adhere to one another
and to aggregate, thereby forming microcolonies. Staphylococcal intercellular adhesins
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that promote biofilm development include surface proteins such as biofilm-associated
protein (Bap), S. aureus surface protein G (SasG), accumulation/adhesion-associated
protein (Aap) and a carbohydrate based adhesin known as polysaccharide intercellular
adhesin (PIA) in S. epidermidis or PNAG in S. aureus (Mack, Fischer et al., 1996; MairaLitràn, Kropec et al.,2002; Corrigan, Rigby et al., 2007).
The fourth stage of development involves the biofilm architecture becoming
larger and more porous. The exopolymeric matrix may be composed predominantly of
PIA/PNAG, however, depending on strain background and environmental conditions,
staphylococcal biofilms that lack such polysaccharides and are primarily proteinaceous,
can form (Frank and Patel, 2007; Rohde, Burandt et al., 2007). A recent study by Hennig
et al. described a spontaneous switch from a polysaccharide based biofilm to biofilm
formation mediated by proteins in an icaC insertion mutant within S. epidermidis
(Hennig, Nyunt Wai et al. 2007). More recently, extracellular bacterial DNA (eDNA),
presumably released by lysed bacteria, has also been observed as a component of the
staphylococcal biofilm matrix (Qin, Ou et al., 2007; Rice, Mann et al., 2007).
Finally, in order to colonize new surfaces the bacteria within the biofilm detach
and disseminate so as to either resume the planktonic lifestyle or to establish a new
biofilm at an alternate location (Stoodley, Wilson et al., 2001). Dispersal is accomplished
by shearing, where pieces of the biofilm can break off in the flow of blood or urine or by
enzymatic dispersal. An example of enzymatic dispersal is seen in Pseudomonas
aeruginosa, which produces an enzyme called alginate lyase that digests the
polysaccharide component of its biofilm, releasing bacteria into the environment (Boyd
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and Chakrabarty 1994). However, such active dispersal processes have not been shown to
occur in the staphylococci.
The matrix of staphylococcal biofilms can be composed of various components
including polysaccharides, proteinaceous adhesins and/or eDNA. These matrix
components are unique in that the bacteria can utilize each of these components
individually or synergistically in order to establish a successful biofilm. The growing
condition and the environmental milieu play critical roles in determining, and potentially
altering, the matrix architecture. Therefore, the intrinsic variability of staphylococcal
biofilms directly relates to, biofilm-related infections that appear to respond to a
therapeutic course of antibiotics, may relapse weeks or even months later, making
surgical removal and replacement of the infected tissues or medical device a frequent and
unfortunate necessity.
Surface-associated virulence factors
Surface-associated virulence factors of S. aureus include structural components of
the cell wall, extracellular polysaccharides, and surface-exposed proteins. Collectively,
these virulence factors play important roles in aiding S. aureus to avoid host defenses and
promote colonization. Colonization is an important aspect of staphylococcal pathogenesis
and, as infection is frequently by autoinoculation, colonization usually precedes infection.
During colonization, the host is not adversely affected although colonization is oftentimes
associated with acute local immune response. Therefore, while colonization is not likely
to harm a healthy individual, it is a risk factor for disease and infection once normal
protective barriers or defenses are weakened. The surface of S. aureus is coated with a
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variety of adhesins capable of binding to different host proteins in plasma and/or the
extracellular matrix: proteins that mediate colonization. These proteins are of paramount
importance in the initial attachment steps associated with biofilm formation.
There are at least 28 different S. aureus surface-associated proteins that promote
the binding of at least 18 different host proteins. These are broadly classified into
MSCRAMMs and SERAMs (secretable expanded repertoire adhesive molecules) (Clarke
and Foster, 2006). These adhesins are critical in establishing infection through the
intimate binding of host-derived proteins. MSCRAMMs bind host extracellular matrix
components including collagen, fibronectin, and fibrinogen. Different S. aureus strains
may have different constellations of MSCRAMMs and so may be predisposed to causing
certain kinds of infections (Patti, Allen et al., 1994; Foster and Hook, 1998). Specific
properties of S. aureus surface proteins that define them as MSCRAMMs include the
presence of a C-terminal sorting signal containing an LPXTG motif followed by a
hydrophobic membrane-spanning region and a positively charged cytoplasmic tail. The
LPXTG motif serves to covalently anchor the MSCRAMM to the cell wall peptidoglycan
via a reaction catalyzed by sortase A (Schneewind, Mihaylova-Petkov et al., 1993). This
group of adhesins include- Protein A (Spa), collagen adhesin (Cna), the fibronectinbinding proteins (FnbA and FnbB) and the fibrinogen-binding clumping factor proteins
(ClfA and ClfB). While MSCRAMMs promote the early stages of biofilm formation,
they also initiate endovascular infections, bone and joint infections, and prosthetic-device
infections (Otto, 2008).
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S. aureus Protein A (Spa) classically functions to prevent antibody-mediated
opsonization by binding to the Fc region of IgG. However, Spa also binds von
Willebrand factor, a large serum glycoprotein that mediates adherence of platelets upon
endothelial damage (Hartleib, Kohler et al., 2000). FnbA and FnbB are MSCRAMMs
that promote binding to fibronectin, a high molecular weight glycoprotein of the host
extracellular matrix. Strains encoding both genes are found more commonly associated
with invasive disease (Peacock, Fay et al., 2000). S. aureus produces two primary
fibrinogen-binding clumping factor proteins designated ClfA and ClfB. Unlike the
fibronectin-binding proteins, the fibrinogen-binding proteins are not contiguous within
the S. aureus chromosome and appear to be fairly well conserved among different strains
(Tristan, Ying et al., 2003). Both ClfA and ClfB promote platelet aggregation, and this
has been shown to contribute to the development of infective endocarditis (Moreillon and
Que, 2004). ClfA, and to a lesser extent ClfB, was shown to promote virulence in an
experimental endocarditis model (Entenza, Foster et al., 2000; Vernachio, Bayer et al.,
2003).
The ability of S. aureus to adhere to plasma and extracellular matrix proteins
deposited on biomaterials is a significant factor in the pathogenesis of device-associated
infections. Once S. aureus adheres to host tissue or prosthetic material, encased within
host extracellular matrix components using the above mentioned surface-associated
proteins, the bacteria can develop into tenacious biofilms which are refractory to the
immune system and antimicrobials leaving device removal or tissue replacement as the
lone therapeutic alternative.
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Regulation of virulence factors
In order to control its normal cellular functions involved in metabolism and
growth, S. aureus must have efficient ways to respond quickly to an infinite number of
environmental stimuli including antibiotics, phagocytes, cell density, complement, etc.
These external signals and stimuli exert their appropriate phenotypic effects through the
coordinated action of internal regulators. Thus, S. aureus regulates its plethora of
virulence factors in a manner that is specific and appropriate for the current stage of
colonization or infection. To accomplish this large feat, S. aureus has multiple regulatory
mechanisms involving three sigma factors, 16 two-component systems, a quorum sensing
system through the Agr/RNAIII pathway and a large repository of transcriptional
regulators (George and Muir, 2007; Somerville and Proctor, 2009; Pragman and
Schlievert, 2004). While these regulatory elements control a wide variety of genes
involved in the pathogenic potential of S. aureus, this review will be limited to the
coordinated activity of two major global regulatory elements: sarA (staphylococcal
accessory regulator A) and agr (accessory gene regulator) as they relate to biofilm
formation (Figure 3).
The staphylococcal accessory regulator A, SarA is the prototype for the 11member Sar family of DNA binding regulators that S. aureus uses to respond to changing
local environments (Cheung, 2008). SarA is a DNA binding protein that is known to
regulate the expression of many virulence factors, especially extracellular proteases, cell
wall proteins and biofilm formation (Bronner, Monteil et al., 2004; Beenken, Blevins et
al., 2003; Karlsson and Arvidson, 2002; Chien, Manna et al., 1999). Expression of SarA
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Figure 3. Balance between SarA and Agr during S. aureus biofilm formation. Two
major regulators associated with biofilm formation- Agr and SarA work in concert with
one another. Staphylococcal accessory regulator A (SarA) is a global regulator that is
primarily expressed during early-mid exponential phase of growth. SarA positively
regulates virulence factor expression through increased expression of surface-associated
proteins involved in initial colonization and biofilm formation while simultaneously
downregulating expression of extracellular proteases and exoenzymes. Crowding during
post-exponential phase activates the accessory gene regulator (agr) system that stimulates
toxic exoprotein production enabling the bacteria to release themselves from the biofilm
and spread to new sites of colonization.
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is dependent upon growth phase, with its greatest expression observed during the early to
mid-exponential growth phase. Thus, it can regulate virulence determinants in a temporal
manner, upregulating surface-associated proteins involved in initial colonization and
biofilm formation like the fibronectin-binding proteins (FnbA and FnbB) (Cheung,
Koomey et al., 1992; Xiong, Bayer et al., 2004). SarA acts by either directly binding to
the promoter region, stabilizing mRNA, or indirectly through other regulators such as the
Agr system (Bronner, Monteil et al., 2004). In addition, SarA is a positive regulator of ica
(intercellular adhesin) operon transcription, which is associated with PNAG production
and thus enhances polysaccharide production and biofilm formation (Tsang, Cassat et al.,
2008). Mutation of sarA leads to decreased biofilm formation and increased antimicrobial
susceptibility in S. aureus (Weiss, Spencer et al., 2009). One can theorize that SarA is
turned on when cells are at a high enough density where adherence to tissues is desired.
In considering biofilm formation and adaptive physiology of Staphylococcus,
quorum sensing is an important phenomenon. Many bacterial behaviors including
growth, biofilm formation, and antibiotic resistance are regulated by quorum sensing
(Keller and Surette, 2006). Quorum sensing is the perception of a critical density of a
secreted molecule (autoinducer) by a bacterial cell that results in a change in gene
expression. This will occur when the bacterial population reaches a certain density or
“quorum” within a confined space. Staphylococci possess two quorum-sensing systems,
the agr system and the luxS system that negatively influence biofilm formation. The agr
locus contains two divergent promoters, P2 and P3, which encode for the RNAII and
RNAIII transcripts respectively. RNAIII is the effector molecule of the agr response and
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is responsible for upregulating extracellular proteases and exoenzymes including hla (αtoxin) (Morfeldt, Taylor et al., 1995; Oscarsson, Kanth et al., 2006) and sspA (serine
proteinase) (Oscarsson, Tegmark-Wisell et al. 2006), and downregulating of cell wall
associated proteins, such as the fibronectin-binding proteins (FnbA and FnbB) and spa
(protein A) (Novick, Ross et al., 1993) during the post-exponential phase.
As illuminated in Figure 3, the two global regulators- SarA and Agr play
opposing roles within S. aureus biofilm formation. During early stages of the biofilm
development through exponential phase, SarA accounts for increased expression of
surface-associated adhesins and repression of extracellular enzymes including proteases
and nucleases. As the biofilm matures, the increasing cell density turns ‘on’ the Agr
quorum sensing system, which serves to prevent the biofilm from becoming too large and
acts as a mechanism for dispersal through decreased expression of surface proteins and
increased expression of secreted protease.

Research Objectives
Due to the clinical gravity and high morbidity and mortality associated with S.
aureus infections, identification of compounds that the bacterium would encounter in
vivo and their effects on biofilm formation is paramount. That said, this project first
elucidates the role of host serum components, and thereafter, the effect of chelators and
catheter lock solutions on S. aureus biofilm formation. These objectives have resulted in
identification of novel host-derived serum components that successfully inhibit strains of
S. aureus from establishing biofilms. Additionally, this project has revealed a novel
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outlook on the role of chelators and their proposed antibiofilm properties; being limited
only to a subset of strains. This study revealed a newly defined subgroup of strains that
counter the inhibitory effects of these chelators and catheter lock solutions. Knowledge
and understanding the role these compounds have within S. aureus biofilm formation can
provide new insight into alternative therapeutics against this, clinically relevant,
developmental process.
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CHAPTER 2
Materials and Methods

Strains and culture conditions. Bacterial strains used in these studies are listed in Table
1. S. aureus strains were grown on Tryptic Soy Agar plates (TSA) (BD, Sparks, MD), or
TSA plates, supplemented with the appropriate antibiotic as required for selection, at 37
°C overnight, or as indicated. Liquid cultures of S. aureus were grown in either Tryptic
Soy Broth (TSB) (EMD Chemicals Inc, Gibbstown, NJ) with or without addition of 1%
D-Glucose (TSBG) (Fisher Scientific, Fair Lawns, NJ) at 37 °C overnight with shaking at
200 rpm. E. coli strain CH3 Blue was grown in LB (EMD Chemicals Inc, Gibbstown,
NJ), either as broth or on plates at 37 °C overnight. The following antibiotics were
incorporated into the media when appropriate: 10 µg/mL erythromycin (Erm), 100 µg/mL
ampicillin (Amp), 35 µg/mL chloramphenicol (Cm), 5 µg/mL tetracycline (Tet). Primers
used throughout these studies are listed in Table 2.

Static biofilm assay. Biofilm assays were performed essentially as described previously
by Christensen et al. (Christensen, Simpson et al., 1985). Briefly, overnight planktonic
cultures of S. aureus were diluted to a final OD600nm of 0.015 in fresh media and 200 µL
of the culture was aliquoted into individual wells of a 96 well Cell Culture plates
(Cellstar, Greiner Bio-one, Monroe, NC). The cells were grown in Tryptic Soy Broth
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Table 1. Bacterial strains used in this study
S. aureus Strains

Description

Source

SA113

ATCC 35556; PNAG-dependent biofilm
producer

Iordanescu and
Surdeanu, 1976

SA113 Δica::tet

ica mutant of S. aureus SA113 (Tetr)

Cramton, Gerke et al.,
1999

MN8

Clinical isolate from nonmenstrual toxic shock
syndrome case

Schlievert and Blomster,
1983

MN8 Δica::tet

ica mutant of S. aureus MN8 (Tetr)

Jefferson, Cramton et al.,
2003

RN450

NCTC8325 cured of Φ11, Φ12, and Φ13

Novick, 1967

agr mutant of S. aureus RN450 (Tetr)

Novick, Ross et al., 1993

RN4220

Restriction defective derivative of RN450

Kreiswirth, Lofdahl et al.,
1983

RN4220 ΔclfB::erm

clfB mutant of S. aureus RN4220 (Ermr)

This study

10833

ATCC 25904; Clinical isolate from a throat
swab, clumping factor-positive variant of
Newman

Cramton, Gerke et al.,
1999

10833 ΔclfB::erm

clfB mutant transduced from RN4220
ΔclfB::erm (Ermr)

This study

10833 ΔclfB / pCL15-clfB

Complementation of clfB mutant in trans using
pCL15 (Cmr)

This study

10833 Δaur::Tn

aur Tn mutant transduced from NE163 (Ermr)

This study

10833 Δaur / pCL15- 10833-aur

Complementation of aur mutant in trans using
pCL15 and 10833 aur sequence (Cmr),

This study

10833 Δaur / pCL15- Newman-aur

Complementation of aur mutant in trans using
pCL15 and Newman aur sequence (Cmr),

This study

Newman

ATCC 31153; Clinical isolate from
osteomyelitis, produces clumping factor

Duthie and Lorenz, 1952

Newman Δagr::tetM (Colony A)

Single colony from agr mutant transduced
from RN450 Δagr::tetM (Tetr)

This study

Newman ΔclfB::erm

clfB mutant transduced from RN4220
ΔclfB::erm (Ermr)

This study

Newman ΔclfB / pCL15-clfB

clfB mutant of S. aureus Newman (Ermr)
complemented in trans using pCL15 (Cmr)

This study

Newman Δaur::Tn

aur Tn mutant transduced from NE163 (Ermr)

This study

Newman Δaur / pCL15- 10833-aur

Complementation of aur mutant in trans using
pCL15 and 10833 aur sequence (Cmr),

This study

RN450 Δagr::tetM
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Newman Δaur / pCL15- Newman-aur

Complementation of aur mutant in trans using
pCL15 and Newman aur sequence (Cmr),

This study

USA300 JE2

USA300 LAC (MRSA) cured of 3 plasmids
pUSA03, pUSA02, pUSA01

Kennedy, Otto et al., 2008

NE391 (ΔclfB)

Transposon (bursa aurealis, a mariner-based
transposon) insertion of USA300 JE2 within
clfB

NARSA Repository

NE543 (ΔclfA)

Transposon (bursa aurealis, a mariner-based
transposon) insertion of USA300 JE2 within
clfA

NARSA Repository

NE186 (ΔfnbA)

Transposon (bursa aurealis, a mariner-based
transposon) insertion of USA300 JE2 within
fnbA

NARSA Repository

NE551

Transposon (bursa aurealis, a mariner-based
transposon) insertion of USA300 JE2 within a
putative fibrinogen/fibronectin binding protein

NARSA Repository

NE163 (Δaur)

Transposon (bursa aurealis, a mariner-based
transposon) insertion of USA300 JE2 within
aur

NARSA Repository

VF Strain #19 ΔclfB::erm

Clinical cardiac device-associated isolateVF Strain #19, clfB mutant transduced from
RN4220 ΔclfB::erm (Ermr)

This study

VF Strain #24 ΔclfB::erm

Clinical cardiac device-associated isolateVF Strain #24, clfB mutant transduced from
RN4220 ΔclfB::erm (Ermr)

This study

E. coli Strains

CH3 Blue

Description

Chemically competent cells, derivative of E.
coli K12, Cloning strain (Ampr)
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Source

Bioline (Tauton, MA)

Table 2. Primers used in this study.
Name

Sequence

16S RT Fwd

5’-TCCGGAATTATTGGGCGTAA-3’

16S RT Rev

5’-CCACTTTCCTCTTCTGCACTCA-3’

icaA RT Fwd

5’-AAACTTGGTGCGGTTACAGG-3’

icaA RT Rev

5’-GTAGCCAACGTCGACAACTG-3’

sarA RT Fwd

5’-TTGCTTTGAGTTGTTATCAATGG-3’

sarA RT Rev

5’-TTTCTCTTTGTTTTCGCTGAT-3’

sasG RT Fwd

5’-ACCACAGGGTGTAGAAGCTAAATC-3’

sasG RT Rev

5’-CGAGCTTTTCTAACCTTAGGTGTC-3’

sigB RT Fwd

5’-TTATGGGGCAACAAGATGAC-3’

sigB RT Rev

5’-TAAACCGATACGCTCACCTG-3’

ccpA RT Fwd

5’-AGTGTCGCGTGTTGTTAATG-3’

ccpA RT Rev

5’-AAGTCCACGAGCAAGTTGTG-3’

fnbA RT Fwd

5’-ATCAGCAGATGTAGCGGAAG-3’

fnbA RT Rev

5’-TTTAGTACCGCTCGTTGTCC-3’

fnbB RT Fwd

5’-AAGAAGCACCGAAAACTGTG-3’

fnbB RT Rev

5’-TCTCTGCAACTGCTGTAACG-3’

clfA RT Fwd

5’-CTGGGCTTCAGTGCTTGTAG-3’

clfA RT Rev

5’-TCCTGTTGTGCTGGATTTTG-3’

clfB RT Fwd

5’-TCGAACGATACAACGCAATC-3’

clfB RT Rev

5’-TGTTGAAGCTGGCTCTGTTG-3’

clfB Soe 1

5’-AGATCTGCACAAGGTAAGTTTGTGGA-3’
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clfB Soe2

5’-CTCGAGCGTCTAATCGAATACTTATT-3’

clfB Soe3

5’-CAGAATAAGTATTCGATTAGACGCTC-3’

clfB Soe4

5’-AGATCTCCTTGTTCAATTCAGCAATGA-3’

clfB-pCl15 Fwd

5’-GGGAAAGGGCTCCAGTTGAAAAAAAG-3’

clfB-pCl15 Rev

5’-GGGAAAGGGGAATTCTTACGCTTTTT-3’

RNAIII RT Fwd

5'-AATTAGCAAGTGAGTAACATTTGCTAGT-3'

RNAIII RT Rev

5'-GATGTTGTTTACGATAGCTTACATGC-3'

clfBPROFWD

5’-TGTTGTTAAAGATCATAAAAATTGGTT-3’

clfBPROREV

5’-TTACGCTTTTTCTTTATGATCTTGCTTG-3’

ClfBRACE

5’-GTACCTACTGTAAAACGTCTAATCG-3’

ClfBRACEnest

5’-TCGAATACTTATTCTGCTTATTCGAC-3’

aur-pCl15 Fwd

5'-GTGAGGAAATTTTCAAGATATG-3'

aur-pCl15 Rev

5'-TTACTCCACGCCTACTTCATTCC-3'

aur-Seq-ExtFwd

5'-CGATTATTGCGTCTTACATAGTTG-3'

aur-Seq-ExtRev

5'-AGACAACCCTCACACTCCTCTC-3'

aur-Seq-IntFwd

5'-GTATTGACGGTGGATTTAGCC-3'

aur-Seq-IntRev

5'-GCACGTTGCTCATCTTTTACG-3'
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(TSB) supplemented with 1% glucose (TSBG). Additional reagents or compounds were
supplemented as per the requirements for each individual experiment. The plates were
incubated at 37 °C for 18 h, spent medium was removed, and the wells were washed once
with 200 µL of sterile water, dried and stained with safranin. The biofilms were visually
analyzed using a flatbed HP color LaserJet 2820 scanner (Hewlett-Packard Company)
and quantified by dissolving the stain with 200 µL 33% (v/v) acetic acid and determining
the OD415nm using a 96-well plate spectrophotometer (BioTek 800 Plate reader, Winooski,
VT). Replica plates were used to determine growth at OD595nm. Results for these
experiments were compiled from three biologic replicates each of which contained five
technical replicates.

Dispersal/Protection Assay. S. aureus biofilms were pre-established on individual wells
of a 96-well Cell Culture plates using the appropriate strain inoculated into the respective
media condition as described above. After 18 h incubation, the wells were removed off
their media and replaced with an equivalent volume of varying concentrations of metallic
cations, diluted in sterile deionized water, or recombinant Aureolysin metalloprotease
synthesized from S. aureus strain V8-bc10 (Axxora LLC., San Diego, CA), diluted in 1X
PBS, and incubated for another 18 h at 37 °C without any shaking. The biofilms retained
on the plate were then treated as before i.e. washed for any non-adherent or dispersed
cells with 200 µL of sterile water, dried and stained with safranin. Quantification of any
detectable biofilm was thereafter performed as described above.
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Quantification of free calcium (Ca2+). The concentration of free calcium ions (Ca2+) in
TSB, TSBG, and TSB supplemented with different concentrations of EGTA was
determined using the QuantiChrom™ Calcium Assay kit (BioAssay Systems, Hayward,
CA) according to manufacturer’s instructions. TSB with varying concentrations of added
Ca2+ was used to ensure accuracy and efficiency of the kit.

Confocal Microscopy of S. aureus biofilms. Diluted overnight cultures of S. aureus strain
SA113 were grown for biofilms within wells of a 6-well plate (Cellstar, Greiner Bio-one,
Monroe, NC) under calcium replete (TSBG + 12.5 mM Ca2+), calcium deplete (TSBG +
12.5 mM EGTA) or calcium reconstituted (TSBG + 12.5 mM Ca2++ 12.5 mM EGTA)
conditions. Biofilms were grown overnight at 37 °C for 18 h without any shaking. The
wells were then washed for their media and non-adherent cells with an equivalent
volumes of sterile water. Biofilms were stained with 3 µL SYTO® 9 (Green) and 3 µL
propidium iodide (Red) of the Live/Dead BacLight™ stain kit (Invitrogen, Carlsbad, CA)
diluted in 3 mL of PBS for 15 min in the dark. Green-fluorescent SYTO® 9 stain when
used alone labels both live and dead bacteria. In contrast, propidium iodide penetrates
only bacteria with damaged membranes, reducing SYTO® 9 fluorescence when both dyes
are present. Thus, live bacteria with intact membranes fluoresce green, while dead
bacteria with damaged membranes fluoresce red. Biofilms were then washed twice with
PBS solution, and confocal imaging was performed with a multiphoton confocal scanning
laser microscope (Zeiss LSM 510; Microscopy Core Facility, Department of Anatomy
and Neurobiology, VCU, Richmond, VA).
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Scanning Electron Microscopy of S. aureus biofilms. Overnight cultures of strain 10833
were grown for biofilms within TSBG or TSBG supplemented with 12.5 mM EGTA on
glass microscope coverslips that were placed within individual wells of a 6-well plate
(Cellstar, Greiner Bio-one, Monroe, NC). The plate was allowed to incubate at 37 °C for
18 h. The plate and coverslips were washed gently for non-adherent bacteria with
sterilized water. The coverslips were sterilely removed from the wells and placed in a
new 6-well plate. Processing of the cover slips was performed by Ms. Judy Williamson
(Department of Anatomy and Neurobiology, VCU, Richmond, VA). The processed cover
slips were visually analyzed and imaged using a Zeiss EVO 50 XVP scanning electron
microscope (Microscopy Core Facility, Neuroscience Department, VCU, Richmond,
VA).

Characterization of serum components. Small molecular weight components were
separated from FBS by adding 15 mL FBS to Amicon Ultra filter units (Millipore, MA)
with a 3000 MWCO. The samples were centrifuged at 4000 rpm for approximately 60
min at 4 ºC. For some experiments, heat labile components in the <3,000 kDa fraction
were destroyed by heating at 100 ºC for 5 min. In others, proteinaceous serum
components were destroyed by incubating with 0.4 mg/mL proteinase K at 65 ºC for 1 h
followed by incubation at 100 ºC for 5 min to inactivate the protease. All fractions were
filter sterilized prior to use.
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Adherence to catheter tubing. Overnight cultures of 10833 and Newman were diluted to
an OD600nm of 0.015, inoculated into test tubes with TSBG or TSBG containing 12.5 mM
EGTA and a ~2 cm piece of intravenous catheter tubing (BD, Franklin Lakes, NJ) and
incubated at 37 °C for 18 h without shaking. After overnight incubation, the catheter
tubes were sterilely removed, washed once with deionized water, sonicated in 1 mL of
1X PBS and plated on TSA for cfu counts. The assay was performed in triplicate and the
results are represented as the mean cfu count.

Clumping assay. Overnight cultures of bacteria were diluted to a final OD600nm of 0.015
in 2 mL TSBG or TSBG containing 12.5 mM EGTA. The cultures were incubated,
without shaking, at 37 °C for 18 h. Tubes were lightly vortexed and visually inspected for
clumping and imaged using a Nikon CoolPix S80 digital camera (Nikon).

Assessment of δ-hemolysis by S. aureus strains. Strains of S. aureus were grown
overnight on TSA plates supplemented with the appropriate antibiotic, if needed. A single
colony was isolated to be restreaked onto Brucella Blood agar plates (Oxyrase,
Mansfield, OH) and grown overnight at 37 °C for 18 h. A zone of clearing around the
streaked cultures was deemed a positive identification of hemolytic activity. The plates
were set atop a light box and imaged.

RNA Isolation. Samples were separated by centrifugation at 4,000 rpm at 4 °C for 15 min
in an Eppendorf 5810R centrifuge (Eppendorf, Hamburg, Germany), the spent media was
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discarded and pellets were frozen immediately at -80 °C until use. RNA was extracted
using the Qiagen RNeasy® mini kit (Qiagen, Valencia, CA) with some modifications.
Samples were resusupended in 500 µL of Qiagen Buffer RLT and added to 2 mL tubes
containing 1 mm glass beads (Research Products International Corp., Mount Prospect,
IL) or Lysing Matrix B® tubes (MP Biomedicals, Solon, OH). 500 µL cold acid phenol
was added and the cells were lysed twice using FastPrep FP120 (Thermo, Pittsburgh, PA)
at a speed setting of 6.0 for 45 s. The tubes were cooled for 5 min on ice between the
runs. Samples were centrifuged at 14,000 rpm for 10 min at 4 °C. The aqueous phase was
collected and 500 µL 100% ETOH (Invitrogen, Carlsbad, CA) was added and mixed.
Samples were then loaded into the RNAeasy column (Qiagen). Following the
manufacturers’ instructions, columns were washed with 700 µL RW1 (Qiagen) followed
by 2X washes of RPE (Qiagen). The RNA was eluted twice with 50µl nuclease-free H20.
Contaminating DNA was digested with Turbo DNase (Ambion, Austin, TX) for 1 h at 37
°C. Turbo DNAse was inactivated and removed using DNAse Inactivation Reagent
(Ambion) according to manufacturers instructions. The absorbance of each RNA sample,
post DNase treatment, was measured at 260 and 280 nanometers using either a NanoDrop
1000 (Thermo Scientific, Milford, MA) and the ratio of these two values was used to
determine the relative purity and concentration of the RNA samples.

5’ Race Analysis. The clfB transcriptional start site was determined using the FirstChoice
RLM-RACE kit (Ambion). 10 µg RNA was incubated in 1X reaction buffer in a 20 µL
total volume with 1 U of Terminator enzyme (Epicentre Biotechnologies, Madison, WI),
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a 5’ mono-phosphate dependent exonuclease, to degrade rRNA, tRNA, and partially
degraded mRNA for 1 h at 37 °C. The reaction was then terminated by phenol extraction
and ethanol precipitation and the RNA was subjected to 5’-RACE analysis according to
manufacturer’s protocol. Primer ClfBRACE was used for the initial PCR reaction and
ClfBRACEnest was used for the nested PCR. The nested PCR product was cloned in
pCR4TOPO (Invitrogen) and sequenced (Eurofins MWG Operon).

cDNA synthesis. cDNA was synthesized from 4 µg of isolated mRNA by a two-step
reverse transcriptase reaction using the Bioline Tetro cDNA synthesis kit (Bioline,
Tauton, MA) according to manufacturer’s instructions. The RNA and 10 pmol of gene
specific reverse primer (Table 2) in a 10 µL volume were heated at 70 °C for 10 min and
then incubated on ice for 2 min. The reverse transcriptase master mix containing 5X RT
Buffer, 10 mM dNTPs, RNase Inhibitor, and RT enzyme is aliqouted into each sample
for an additional volume of 10 µL. The reactions were incubated at 42 °C for 2 h,
followed by 70 °C for 15 min. Control reactions lacked reverse transcriptase enzyme.

Quantitative RT-PCR. Realtime RT-PCR reactions contained 2 µL cDNA or no-RT
control (diluted 1:500 for 16S reactions and 1:5 for other genes), 1 pmol forward and
reverse primers, 8.5 µL nuclease free deionized water and 12.5 µL SYBR Green
Sensimix™ (Bioline, Tauton, MA). Realtime RT-PCR was performed using an iQ5
Multicolor Realtime PCR (BioRad, Hercules, CA) under the following conditions: 94 °C
for 2 min, 40 cycles of 94 °C for 10 s, 54 °C for 15 s, 72 °C for 15 s. The normalized
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amount of transcript for each gene was expressed as the n-fold difference relative to the
control gene (2ΔCT, where ΔCT represents the difference in threshold cycle between the
target gene and the 16S rRNA gene). Averages were obtained from technical replicates
and standard deviation was determined. Biological triplicates were performed for each
sample.

gDNA Extraction. Genomic DNA was extracted from S. aureus cells streaked onto TSA
plates supplemented with the appropriate antibiotic, if necessary. Post overnight
incubation, a small loop of culture was removed from the respective plate and
resuspended in 200 µL Lysostaphin (5.0 mg/mL) (Sigma, St. Louis, MO) diluted in 1X
TE buffer (10mM Tris-HCl pH 7.5, 1 mM EDTA) and incubated for 30 minutes at 37ºC.
Samples were then incubated with 25 µl of Qiagen Proteinase K solution (20 µg/mL
stock) (Qiagen, Valencia, CA) and 200 µL Qiagen Buffer AL at 56 ºC for 30 min. The
samples were treated with 200 µl of EtOH and transferred into Qiagen DNeasy Mini Spin
columns. DNA was thereafter extracted according to the Qiagen Blood and Tissue Kit
protocol. DNA was eluted off the columns twice with 50 µL of Qiagen Buffer AE.

DNA and Plasmid manipulations. DNA was gel purified using the QIAquick Gel
Extraction Kit (Qiagen, Valencia, CA) as described by the manufacturer. All restriction
enzymes, specific buffers and BSA used for restriction enzyme digests of miniprep DNA
or PCR fragments were purchased from New England Biolabs (Ipswich, MA) and used as
recommended by the supplier. Removal of phosphoryl groups from the 5’ ends was
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accomplished with Antarctic Phosphatase (New England Biolabs, Ipswich, MA) using
the supplied buffer. Ligations used Ready-To-Go™ T4 DNA Ligase and Ligase Buffer
(Amersham Biosciences, Piscataway, NJ). PCR products were purified using QIAquick
PCR purification kit (Qiagen, Valencia, CA) as recommended by the manufacturer.
Plasmid mini-preps were prepared from individual E. coli transformants that were grown
overnight in 3 ml of LB broth with ampicillin, using a QIAprep Spin Miniprep kit
(Qiagen, Valencia, CA,) as described by the manufacturer.

Agarose gels. Agarose gels were prepared by dissolving agarose in 1X Tris-AcetateEDTA (TAE) buffer (Fisher Scientific, Pittsburgh, PA). Ethidium bromide was added to
0.15 µg/mL prior to pouring the gel. PCR products, diluted in 10X BlueJuice gel loading
buffer (Invitrogen) for a final concentration of 1X, were run on a 1.0% agarose gels.
Gels were run at 125 volts until the dye front had migrated roughly ¾ of the length of the
gel and then visualized under UV light. DNA size was measured against the Hyperladder
(BioLine, Taunton MA) series of DNA MW markers.

Competent cell preparation. Electrocompetent S. aureus RN4220 cells were prepared
from overnight cultures grown in TSB at 37 °C with shaking. Cultures were subcultured
in fresh media (1:100 dilution) and were grown to exponential phase (OD600nm ~ 0.5). The
cultures were collected by centrifugation for 15 min at 4,000 rpm at 4 °C. Care was taken
to ensure all subsequent steps were performed on ice. The pellet was then washed three
times with 25 mL of ice cold sterile water. The pellet was then washed one time in 30 mL
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of ice cold sterile 10% glycerol. The pellet was then resuspended in 15 mL of ice-cold
sterile 10% glycerol and incubated at room temperature for 15 min. The final bacterial
pellet was resuspended in 500 µL sterile 10% glycerol. Aliquots (50µl) were then flash
frozen in a dry ice/EtOH bath and were stored at -80 °C until use.

Transformation. One vial of chemically competent CH3-Blue E. coli cells (50 µL) was
thawed out on ice. Ligation reactions (3 µL) were added competent E. coli cells mixed
gently and incubated on ice for 10 min. The tubes were then transferred to a water bath
set to 42 °C for 30 s and then put back on ice for 5 min. The cells were then added to 0.25
ml of SOC media (2% wt/vol) tryptone, 0.5% (wt/vol) yeast extract, 85.5 mM NaCl, 2.5
mM KCl, 10 mM MgCl2, 20 mM glucose) and incubated for one hour at 37°C with
shaking. Following this recovery period the cells were plated on LB plates with
appropriate antibiotic selection.

Plasmid DNA isolated as described above was used to transform electrocompetent S.
aureus RN4220. Plasmid DNA (7.5 µL) was added to a 50 µL aliquot of
electrocompetent S. aureus and incubated on ice for 10 min. The mixture was then
transferred to an electroporation cuvette with a gap length of 0.1 cm and pulsed one time
using the MicroPulser (Bio-Rad, Hercules, CA) pre-set S. aureus setting Sta (1.8 kV, 2.5
msec, 25 µF). Following electroporation, 0.5 mL of TSB supplemented with the
appropriate antibiotic was added immediately to the cuvette and this mixture was then
transferred to a glass culture tube. The antibiotic to be used for selection was added at a
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subinhibitory concentration (erythromycin = 0.05 µg/mL) and the cells were incubated
for 1.5 h with shaking at 37 °C. Aliquots (100 µL and 200 µL) were then spread on TSA
supplemented with appropriate antibiotic selection and incubated at 30 °C for 48 h.

Phage Transduction. The generalized transducing phage 80α was used to create allelic
exchange mutations in S. aureus RN4220. A freezer stock of the respective donor strain
carrying the mutation to be mobilized was inoculated onto TSA supplemented with the
appropriate antibiotic, and grown overnight at 37 ºC. A single colony was subcultured
onto a new plate and allowed to grow overnight at 37 ºC. All of the culture was removed
from the plate and resuspended in 0.5 mL of TSB in a small tube. 200 µL of this culture
was added to 0.4% soft agar in a new tube, along with 5 µL of 2M CaCl2 and either 75
µL of phage 80α or no phage. This mixture was plated onto TSA plates and monitored
for lysis. Following lysis, the soft agar was collected, centrifuged, and the supernatant
was filter sterilized through a 0.45 µm filter. Aliquots of this lysate, either 75 or 150 µl,
were then mixed with 150 µL of recipient bacteria, and 5 µL of 2M CaCl2. The mixture
was incubated with shaking at 37 ºC for exactly 20 min. 5 mL of 20 mM sodium citrate
was added, the culture was centrifuged to pellet the bacteria, the pellet washed twice with
20 mM sodium citrate, then incubated for 1.75 h in 500 µL of 20 mM sodium citrate.
Finally, the mixture was plated on TSA supplemented with the appropriate donor
antibiotic and sodium citrate and these plates were incubated for 48 hours at 37 ºC.

Construction of clfB deletion and complementation mutants. The clfB gene was replaced
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with an erythromycin resistance cassette in S. aureus strain RN4220 by homologous
recombination using the pMAD vector (kindly provided by Michel Débarbouillé and
Maryvonne Arnaud, Pasteur Institute, Paris, France) as previously described by Arnaud et
al. (Arnaud, Chastanet et al., 2004). Genomic DNA from strain SA113 was used as a
template for PCR using primers clfBSoe1 and clfBSoe4 and the PCR product was cloned
into pCR4-TOPO (Invitrogen, Carlsbad, CA). The resulting construct was amplified
using primers clfBSoe2 and clfBSoe3, digested with XhoI, and ligated to an erythromycin
(erm) resistance cassette excised from plasmid pSC57 with XhoI. The resulting plasmid
was digested with BamHI and the region surrounding clfB gene and the intervening erm
cassette were ligated to pMAD. This construct was electroporated into strain RN4220
(Lee, 1995). Once gene replacements in RN4220 were confirmed, the mutations were
then transduced into S. aureus strains 10833 and Newman using phage 80α (Kasatiya and
Baldwin, 1967) and transductants were selected on TSA plates containing 10 mg
erm/mL.
For complementation of the deletion, clfB was cloned into the isopropyl-β-Dthiogalactopyranoside (IPTG)-inducible vector pCL15 (Luong and Lee, 2006). Primers
clfB-pCL15Fwd and clfB-pCL15Rev were used to amplify the clfB gene from strain
SA113 genomic DNA. The PCR product was digested with BamHI and EcoRI and
ligated to pCL15 to produce clfB-pCL15. Plasmids were purified and transformed into
RN4220 and selected on TSA containing chloramphenicol (cm) before the constructs
were transduced into strains 10833 and Newman by phage 80α. Strains harboring clfBpCL15 or pCL15 empty vector were cultured in the presence of 10 mg cm/mL and
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induced in the presence of 1 mM IPTG.

Construction of aur deletion and complementation mutants. The aur transposon insertion
mutations within strains 10833 and Newman were generated by phage transducing the
mutation from the NARSA NE163 strain essentially as described above (Kasatiya and
Baldwin et al., 1967). The resultant transductants were selected on TSA plates containing
10 mg erm/mL.
For complementation of the deletion, aur from 10833 or Newman was cloned into
the isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible vector pCL15 (Luong and Lee,
2006). Primers aur-pCL15Fwd and aur-pCL15Rev were used to amplify the aur gene
from 10833 or Newman genomic DNA. The PCR product was digested with BamHI and
KpnI and ligated to pCL15 to produce Newman-aur pCL15 or 10833-aur pCL15.
Plasmids were purified and transformed into RN4220 and selected on TSA containing
chloramphenicol (cm) before the constructs were transduced into the aur mutant strains
of 10833 and Newman by phage 80α. Strains harboring aur-pCL15 were cultured in the
presence of 10 mg cm/mL and 1 mM IPTG

Antibody mediated inhibition of aggregation and clumping. Overnight cultures of S.
aureus strains were diluted and added to test tubes containing TSBG or TSBG + 12.5
mM EGTA and 4.0 µg/mL α-ClfB antibody or rabbit pre-immune sera or the absence of
any added antibody. The tubes were additionally supplemented with 1 mM IPTG for
induction of complementation constructs. The tubes were incubated at 4 °C for 2 h to
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promote antibody binding and thereafter moved to 37 °C for 18 h without shaking. Tubes
were lightly vortexed and visually inspected for clumping and imaged using a Nikon
CoolPix S80 digital camera (Nikon).

Antibody mediated inhibition of biofilm formation. Overnight cultures of each strain of S.
aureus were diluted to a final OD600nm of 0.015 and inoculated in TSBG or TSBG + 12.5
mM EGTA and treated with varying concentrations of either α-ClfB antibody or rabbit
pre-immune sera (0.5 – 16.0 µg/mL) or in the absence of any added antibody and added
to wells of a 96-well polystyrene plate (Cellstar, Greiner Bio-one, Monroe, NC). The
plate was incubated at 4 °C for 2 h to promote antibody binding and thereafter moved to
37 °C for 18 h without shaking. Non-adherent cells were removed by washing with water
and adherent bacteria were stained with safranin. Biofilms were imaged using a flatbed
HP color LaserJet 2820 scanner (Hewlett-Packard Company) and quantified by
dissolving the stain with 200 µL 33% (v/v) acetic acid and determining the OD415nm using
a 96-well plate spectrophotometer (BioTek 800 Plate reader, Winooski, VT). The
percent inhibition of biofilm formation was determined using the formula: [1(Biofilm415nm (with antiserum) / Biofilm415nm (without antiserum)] ✕ 100 (Hussain, Herrmann et al.,
1997). Growth of the bacterial culture was also assessed to ensure high concentrations of
the antibody did not interfere with growth. Therefore, specific wells targeted for growth
assessment were resuspended by pipetting and read at OD595nm.

Sequence analysis of clfB promoter and aur from 10833 and Newman. Genomic DNA
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was isolated from 10833 and Newman using the DNeasy tissue kit (Qiagen). The clfB
gene and 0.4 kb 5’-proximal to the gene were amplified using primers clfBPROFWD and
clfBPROREV and were sequenced (Eurofins MWG Operon, Huntsville, AL).
The aur gene was PCR amplified using a pair of external primers (aur-Seq-ExtFwd
and aur-Seq-ExtRev) and a pair of internal primers (aur-Seq-IntFwd and aur-SeqIntRev). The external primers covered 0.35 kb 5’-proximal and 0.15 kb 3’ of the gene
while the internal primers were generated to provide a 0.095 kb overlap during the
amplification. The PCR amplicons were sequenced at the VCU Nucleic Acids Core
Facility under the supervision of Dr. Gregory Buck. The sequence analysis and alignment
was performed using Serial Cloner 2.1 and sequence translation was done using the
StartORF 1.0.
All PCR reaction mixtures contained 2.5 mM dNTPs, 5X Phire Buffer, 1000 pM
forward and reverse primers, F-120S Phire Hot start polymerase (Finnzymes, Espoo,
Finland), nuclease free water, and gDNA. Conditions for the all the PCR reactions were
as follow, one initial cycle at 94 °C for 2 min, followed by 35 cycles of- 94 °C for 30 s to
denature, 54 °C for 30 s to hybridize, and 72 °C for 30 s for extension. One final
extension at 72 °C for 5 min after the final cycle and thereafter reactions were cooled to 4
°C before being sent off for sequencing.

Poly-N-acetyl glucosamine (PNAG) blot. Overnight cultures of wildtype SA113, MN8
and their isogenic ica operon deletion mutants were grown in TSBG. Strain 10833 was
grown overnight in either TSBG or media with 12.5 mM EGTA. Cultures were
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centrifuged to pellets and were standardized before being resuspended in 0.5 M EDTA
(Surface-associated fraction). The supernatants from the pellets (Secreted fraction) and
the Surface-associated fractions were boiled for 5 min then centrifuged to pellet cell
debris. The supernatant was transferred to a new tube, 20 µL of proteinase K was added
to each sample and was heated at 65 ºC for 1 h. Samples were boiled for 5 minutes to
inactive the proteinase K. Samples were briefly sonicated for 3-5 seconds and dilutions
made in 1X PBS. A piece of nitrocellulose blotting membrane (BioTrace NT, Pall
Corporation, Ann Arbor, MI) was cut to fit inside the blot apparatus (7.5 cm wide by 11.5
cm long). The cover paper was removed from the nitrocellulose and the membrane was
soaked in 50 mL of 5% methanol for 1-2 minutes. The nitrocellulose membrane was
rinsed in 50 mL of 1X PBS; the nitrocellulose membrane was placed within the blotting
apparatus and care was used to ensure that the instrument gasket had produced a tight
seal. 200 µL of stock or diluted PNAG samples from each fraction were loaded into
individual wells of the blotting apparatus and the machine was allowed to run for 20
minutes or until all the sample was soaked up by the membrane. The membrane was
removed carefully and allowed to dry overnight between pieces of kimwipe.
The dried nitrocellulose membrane was soaked in 25 mL of 5% bovine serum
albumin (BSA) solution, diluted in 1X PBS, for 1 h at room temperature on a rocker. The
membrane was probed with 15 mL of primary antibody solution containing 3 µL of goat
α-PNAG antibody (1:5000 dilution), 1 ml 5% BSA solution, and 14 mL of 1X PBS for 3
h at room temperature on a rocker. The membrane was washed 3X with 15 mL of 1X
PBS for 7 min each. After the wash steps, the membrane was probed with l5 mL of
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secondary antibody solution containing 1.5 µL of rabbit α-goat-HRP labeled antibody
(1:10,000 dilution) and 15 mL of 1X PBS for 1 h at room temperature on a rocker. The
membrane was again washed 3X with 15 ml of 1X PBS for 7 min each. The blot was
incubated in ECL™ Plus chemiluminescence developing reagent (GE Healthcare,
Piscataway, NJ). The blot was then wrapped in saran wrap, exposed to X-ray film, and
developed in an X-O-Mat.

Western blot analysis. S. aureus strains 10833, Newman, USA 300 JE2, and their
isogenic chromosomal or tansposon insertion mutants were grown stationarily for 18 h in
tubes containing TSBG or added 12.5 mM EGTA. The bacteria were collected by
centrifugation of the media at 4000 rpm at 4 ºC for 15 min. Protein amount was
standardized by pellet weight after centrifugation to collect the bacteria. Total bacterial
surface protein was extracted using 0.5 µg/mL of lysostaphin treatment, diluted in 1X TE
buffer and incubation at 37 ºC for 45 min. The tubes were briefly sonicated for 3-5 s and
centrifuged at 14,000 rpm at 4 ºC for 10 min. The supernatants were collected and equal
volumes of supernatants were added to 4X NuPAGE LDS loading buffer to achieve a 1X
concentration. The samples were boiled for 10 min prior to gel loading. Protein samples
were loaded onto a NuPAGE pre-cast Novex Bis-Tris 4-12% gradient gel (Invitrogen,
Carlsbad, CA). Gels were run in 1X MES SDS running buffer (Invitrogen) for 1.75 h at
200 V.
Following electrophoresis, the polyacrylamide gel was rinsed in deionized water. A 0.45
µm PVDF membrane (Invitrogen) was wetted in 100% methanol then incubated in 1X
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NuPAGE transfer buffer. Sponges were wetted in the same transfer buffer and used to
surround the gel and membrane to ensure the system remained saturated with transfer
buffer at all times. The transfer was performed at 40 V for 2 h following which the
membrane was blocked overnight in 25 mL of 5% skim milk (Difco, Franklin Lakes, NJ)
diluted in 1X PBS, at 4 ºC overnight on a rocker. The rocker was removed from 4 ºC cold
room and allowed to equilibrate back to room temperature for about 1.5 h before the
membrane was incubated for 2 h at room temperature with shaking in a 1:10,000 dilution
of α-ClfB antibody (4.0 µg/mL) in 1X PBS, 0.15% skim milk and 0.05% Tween-20
(Fisher Scientific, Pittsburgh, PA). The membrane was washed 4 times for 10 minutes
each in 1X PBS-t (supplemented 0.05% Tween-20) followed by a 1 h incubation in a
1:15,000 dilution of goat α-rabbit-HRP conjugate secondary antibody (Invitrogen) in 1X
PBS-t. The membrane was washed four times for 10 min each in 1X PBS-t. The blot was
incubated in ECL™ Plus chemiluminescence developing reagent (GE Healthcare,
Piscataway, NJ). The blot was then wrapped in saran wrap, exposed to X-ray film, and
developed in an X-O-Mat.
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CHAPTER 3
A low molecular weight component of serum inhibits biofilm formation
in Staphylococcus aureus

Introduction
Staphylococcus aureus is one of the leading causes of nosocomial infections. It is
an opportunistic pathogen that can infect a variety of different human tissues leading to
various clinical manifestations ranging in severity from minor purulent infections like
folliculitis to more severe, potentially fatal, conditions like endocarditis and osteomyelitis
(Lowy, 1998). S. aureus has a large arsenal of virulence factors that allow the bacteria to
evade the host immune system, adhere to host tissue, and acquire nutrients from the host
(Foster, 2005). In addition, S. aureus has the capacity to form biofilms, now recognized
as an important virulence factor particularly in the pathogenesis of medical device-related
infections such as intravenous catheter infections.
A biofilm is a community of microorganisms that adheres to a surface and is
encased within an extracellular polymeric matrix. The staphylococci account for more
than half of prosthetic device-related infections and biofilm formation is a key component
to the pathogenesis of such infections (Zimmerli and Ochsner, 2003). The two major
steps associated with this complex developmental process is adherence of the bacteria to
a surface followed by cell-to-cell adhesion (aggregation). In S. aureus, adherence is
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mediated by surface-associated adhesins including, but not limited to, the S. aureus
surface protein G (SasG) (Kuroda, Ito et al., 2007) and fibronectin-binding proteins
(FnbA and FnbB) (O’Neill, Pozzi et al., 2008) while aggregation is brought about, under
certain conditions, by the synthesis of β-1,6 poly-N-acetylglucosamine (PNAG) also
referred to as polysaccharide intercellular adhesion (PIA). First identified in S.
epidermidis and now known to be functionally conserved within S. aureus, the
polysaccharide is synthesized by proteins encoded by the icaADBC operon (Heilmann,
Schweitzer et al., 1996; Cramton, Gerke et al., 1999).
Transcription of icaADBC and subsequent polysaccharide production and biofilm
formation, is negatively regulated by the product of the icaR gene, transcribed
divergently from icaADBC operon. Conversely, biofilm formation is positively regulated
by the global transcriptional regulator SarA and the carbon catabolite protein CcpA
(Conlon, Humphreys et al., 2002; Jefferson, Pier et al., 2004; Seidl, Müller et al., 2009;
Seidl, Goerke et al., 2008; Valle, Toledo-Arana et al., 2003; Beenken, Blevins et al.,
2003). The alternative sigma factor (σB) is also a positive regulator of biofilm formation
but it is not clear how it exerts this function (Rachid, Ohlsen et al., 2000). Together these
intra- and intercellular components, and others, are coordinated to orchestrate the process
of biofilm formation. In addition to these cellular components, extracellular factors play a
key role as well, as they cue the bacterial cell to conditions under which the biofilm mode
of growth is preferable. External cues that inform bacteria that they are in vivo and affect
expression biofilm-related genes are poorly understood. Because S. aureus can form
biofilms on intravenous catheters and other inserted medical devices that come into
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contact with blood, we hypothesized that serum would be an external cue to trigger
biofilm formation. However, we found the opposite to be true; serum inhibited the
biofilm phenotype under certain conditions, and this inhibition occurred at least in part, at
the level of gene expression.

Results
Effect of serum on biofilm formation
Biofilm formation plays a key role in the pathogenesis of medical device-related
infections and in the case of intravenous catheter-related infections and other devicerelated infections, S. aureus is exposed to blood. Furthermore, pre-coating polystyrene
with serum is frequently used as a method to augment biofilm formation (Speziale,
Pietrocola et al., 2009). We therefore hypothesized that biofilm formation would be
induced in serum. To test this hypothesis, the strong biofilm producing type strain SA113
(Figure 4A), and clinical isolate Newman (Figure 4B), a strong-coagulase-producing
isolate from a case of osteomyelitis (Duthie and Lorenz, 1952; Baba, Bae et al., 2008)
were grown in TSBG alone or media supplemented with human serum, fetal bovine
serum or PBS. Both strains were observed to exhibit similar biofilm trends. While TSBG
and TSBG containing 10% or 50% PBS fostered the elaboration of a thick biofilm, in
either strain, addition of 10% or 50% human serum (HS), surprisingly, inhibited biofilm
formation. This inhibitory effect was not limited to human serum as both 10% and 50%
fetal bovine serum (FBS) revealed a similar ablated phenotype (Figure 4A, B red bars).
In order to confirm inhibition of biofilm formation was not due to growth inhibition, we
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measured growth under the same conditions. The optical densities of the cultures after 18
h revealed that the presence of any concentration of human or fetal bovine serum
supported planktonic growth (Figure 4A, B blue bars).

Characterization of the inhibitory component/s
To obtain a crude estimation of the molecular weight of the component(s)
responsible for this novel inhibitory activity of serum observed in Figures 4A and 4B,
components with approximate molecular weights >3000 Da was removed using a
centrifugal concentrator. Large serum proteins such as lactoferrin, apo-transferrin, and
albumin have been shown previously to inhibit bacterial and S. aureus aggregation and
biofilm formation (Ardehali, Shi et al., 2002; Ardehali, Shi et al., 2003; Singh, Parsek et
al., 2002; Hammond, Dertien et al., 2008), but a role for a small molecular weight
component/s has never been established. Therefore, the low (<3000 Da) molecular
weight fraction (LMWF) of fetal bovine (Figure 5) and human serum (Figure 6) were
assessed for inhibition of biofilm formation within strains SA113 and Newman.
Both whole FBS and human serum, retained the ability to effectively inhibit biofilm
formation compared to control TSBG alone or with supplemented PBS in either strain
tested (Figure 5, 6). Surprisingly, the LMWF of either human or fetal bovine serum
continued to inhibit biofilm formation similar to results observed with whole FBS or
human serum. To further investigate the nature of the small molecular weight component
in the LMWF, we heated the <3000 MW fraction to 100 °C for 5 min (HI LMWF).
Heating did not inactivate the inhibitory activity. To eliminate the possibility that a heat
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Figure 4. Serum inhibits S. aureus biofilm formation. Overnight cultures of SA113
(A) and Newman (B) grown in LB were diluted 1:200 and inoculated in: TSBG,
TSBG + 50% or 10% PBS, Human Serum (HS), TSBG + 50 or 10% HS, Fetal Bovine
Serum (FBS), TSBG + 50% or 10% FBS. Biofilms were allowed to form in 96-well
polystyrene plates at 37 °C for 18 h. Non-adherent cells were removed by washing with
1X PBS and the adherent bacteria were dried and stained with safranin. Scanned
representative images of the bacteria that formed biofilms are shown on the right and
quantitative representation of growth versus biofilm formation under the respective
conditions is shown on the left. Growth (blue bars) was determined by resuspending the
bacteria and measuring A595 nm. Biofilm formation (red bars) was assessed by solubilizing
the safranin in 33% (v/v) acetic acid and measuring at A415 nm. Each condition was tested
5 times within each experiment and experiments were performed a minimum of three
times on separate days with similar results and shown here is a representative image.
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Figure 5. The low molecular weight fraction (LMWF) of fetal bovine serum inhibits
biofilm formation. Strains SA113 (A) and Newman (B) were grown for biofilms in 96well plates in TSBG, TSBG + 50% or 10% 1X PBS, Fetal Bovine Serum (FBS),
TSBG + 50% or 10% FBS, <3,000 Da component of fetal bovine serum (FBS LMWF),
TSBG + 50% or 10% FBS LMWF, Heat Inactivated (HI) FBS LWMF, TSBG + 50% or
10% HI FBS LMWF, and Proteinase K (Prot. K) treated FBS LMWF, TSBG + 50% or
10% Prot. K-treated FBS LMWF. >3,000 Da fraction of serum was removed by filtration.
Biofilms were imaged and thereafter read at A415 nm (red bars) to determine biofilm
formation under the respective conditions. Growth was determined within the individual
conditions prior to biofilm washing and staining and measured at A595 nm (blue bars).
Results represent the data from 3 independent experiments.
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Figure 6. The low molecular weight fraction (LMWF) of human serum inhibits
biofilm formation. Strains SA113 (A) and Newman (B) were grown for biofilms in 96well plates in TSBG, TSBG + 50% or 10% 1X PBS, Human Serum (HS), TSBG + 50%
or 10% HS, <3,000 Da component of human serum (HS LMWF), TSBG + 50% or 10%
HS LMWF, Heat Inactivated (HI) HS LWMF, TSBG + 50% or 10% HI HS LMWF, and
Proteinase K (Prot. K) treated HS LMWF, TSBG + 50% or 10% Prot. K-treated HS
LMWF. >3,000 Da fraction of serum was removed by filtration. Biofilms were imaged
and thereafter read at A415 nm (red bars) to determine biofilm formation under the
respective conditions. Growth was determined within the individual conditions prior to
biofilm washing and staining and measured at A595 nm (blue bars). Results represent the
data from 3 independent experiments.
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stable protein was responsible for biofilm inhibition, Proteinase K was used to degrade
proteins in the FBS flow-through (Prot. K treated LMWF) but this did not affect the
ability of this low molecular weight fraction to inhibit biofilm formation. The results
were similar for FBS or human serum in both strains- SA113 and Newman. Together
these results suggest that the compound in serum that inhibits S. aureus biofilm formation
is not proteinaceous. We found in a previous study that basic conditions can inhibit
biofilm formation. Because the pH of serum is slightly basic, we buffered the <3000 Da
fraction to pH 7.0 to determine whether the effect was due to high pH; however, this did
not affect the biofilm-inhibiting activity (Thompson, Abraham et al., 2010).

Serum components affect expression of biofilm-related genes
To determine whether inhibition of biofilm formation occurred at the level of gene
expression, total RNA was isolated from cells grown in TSBG or the LMWF of human
serum and expression levels of specific genes that have been previously implicated in
biofilm formation or regulation were determined by quantitative realtime RT-PCR. The
individual genes were normalized to the 16S rRNA and the relative fold expression of
each gene is shown with respect to the TSBG control (Figure 7). In comparison to
TSBG, expression of the icaA, ccpA, and fnbA and fnbB genes was significantly lower
(by Student’s t-test P<0.002) within the serum fraction. IcaA (Intercellular Adhesin
protein A) is a glucosyltransferase, necessary for the synthesis of PNAG/PIA, the primary
component of S. aureus biofilms. Interestingly, there were strain-variable differences in
the expression of other biofilm-related genes. The serum fraction led to a drastic decrease
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Figure 7. Transcript levels of biofilm associated genes under various media
conditions. Total RNA was isolated from strains SA113 (black bars) and Newman (grey
bars) grown in TSBG or LMWF of human serum during mid-log phase of growth. The
transcript levels of specific genes that have been previously implicated in biofilm
formation were analyzed by realtime RT-PCR. Individual genes were normalized to 16S
rRNA and relative fold expression is shown with respect to TSBG. Each gene was
assessed in triplicate and the experiment itself was performed in biologic duplicate.
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in sasG transcript levels (P<0.0005) in strain SA113 but actually lead to a slight increase
in Newman. SasG is a cell walled anchored protein that functions as an adhesin,
facilitating the initial steps associated with intercellular bacterial binding to the substrate
during biofilm formation (Kuroda, Ito et al., 2008; Corrigan, Rigby et al., 2007).
Furthermore, the level of sarA transcript increased approximately 5-fold in SA113
(P<0.001) but was repressed in strain Newman and levels of the sigB and fnbB transcripts
were inhibited by the serum fraction in SA113 but remained unchanged in Newman
(P>0.05).

Discussion
Tenacious biofilms of S. aureus play an important role in various host infections
including medical device related infections. Additionally, biofilms formed by this
bacterium plays a key role in the pathogenesis of catheter-related infections. Biofilm
development within S. aureus, is facilitated through the coordinated efforts of a variety of
genes that can directly or indirectly influence the process of biofilm formation. The
ability to establish a biofilm is an important virulence factor for this pathogen, and yet,
the regulation of this process in vivo is not well understood. Stressors present in the
environment of a bacterial cell strongly influence its homeostatic and adaptive
physiology. Stress responses are often facilitated by global changes in transcriptional or
post-translational gene expression. Certain stressors including increased temperature,
changes in the availability of glucose, exposure to toxic chemicals such as ethanol and
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antibiotics can induce global changes in gene expression that initiate the switch to a
sessile, biofilm mode of growth.
In order to investigate whether or not serum is conducive to the process of biofilm
formation, we grew two different S. aureus strains, SA113 and Newman, in serum and
analyzed biofilm thickness and expression of biofilm-related genes. Whereas serum
supported planktonic bacterial growth, it was a potent inhibitor of biofilm formation in
either strain tested (Figure 4). These findings were not completely surprisingly since
previous studies have directly implicated large molecular weight components like
lactoferrin, apo-transferrin, and albumin to inhibit aggregation and biofilm formation
(Ardehali, Shi et al., 2002; Ardehali, Shi et al., 2003; Singh, Parsek et al., 2002;
Hammond, Dertien et al., 2008). However, a role for a small molecular weight
component/s within serum has never been established. We found by filtration-mediated
size separation a low molecular weight component of serum (<30000 Da) that prevented
biofilm establishment (Figure 5, 6). Interestingly, serial dilutions of this fraction up to
10% continued to inhibit formation of any detectable biofilm. This suggested that the
inhibitory factor is quite effective at inhibiting biofilm formation.
To further tease apart the nature of this unique component/s we heat inactivated
(HI) this fraction by boiling the LMWF serum to 100 °C for 5 min. 56 °C is typically
used to inactivate the components of the innate immune system including complement.
However, heating this fraction at higher temperatures we performed dual service of
inactivating the smaller components of the innate immune system but additionally,
inactivating other small heat-stable components that may occur within this fraction. Heat
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inactivation of human or fetal bovine serum continued to inhibit biofilms from forming in
either strain. Thus we deduced the component to be heat stable.
Antimicrobial peptides (AMPs) are an important arm of the innate immune
system that target and kill S. aureus. These small cationic peptides, which are found in
virtually all higher organisms, have recently become attractive drug candidates, due to
their natural production in and protection of many host tissues and cell types (Li, Cha et
al., 2007; Zasloff, 2002; Hancock and Diamond, 2000). AMPs are highly effective
against most bacteria, regardless of Gram type, because the external charge on the
bacterial envelope is negative, which differentiates them from eukaryotic cells, which are
typically “seen” as neutral. AMPs act by binding to the bacterial membrane via charge
interactions and form pores within the bacterial membrane (Herbert, Bera et al., 2007;
Kraus and Peschel, 2008). Therefore, to rid the serum components of such AMPs, the
serum LMWFs were treated with proteinase K and thereafter additionally heated to
100 °C to inactivate the proteinase. Biofilm formation within proteinase K treated
fractions was also inhibited revealing the component to be protease-resistant or nonproteinaceous.
Identifying the serum component to be heat-stable and protease-resistant we
explored the transcriptional expression levels of various genes that have been implicated
in biofilm formation or its regulation, when strains were grown within the LMWF of
serum (Figure 7). The serum component resulted in a significant decrease in the
transcription of the intercellular adhesin gene icaA and the fibronectin binding protein
gene fnbA. Transcription of other biofilm-related genes were affected in a strain64

dependent manner. These results reveal that serum inhibits biofilm formation despite the
fact that biofilms form on intravenous catheters. This may suggest that in vivo, biofilm
formation is “selected for” by the force of blood flow and/or immune pressure rather than
“induced” by serum.
These findings indicate that the response of different strains to serum varies and it
is possible that other strains that we did not test, could establish biofilms in the presence
of serum. This is not surprising, as biofilm formation in different strains depends upon
different proteins and polysaccharides, and can even depend on extracellular DNA
(Mack, Fischer et al., 1996; Maira-Litràn, Kropec et al.,2002; Corrigan, Rigby et al.,
2007; Arciola, Campoccia et al. 2005; O'Neill, Humphreys et al. 2009; Rice, Mann et al.,
2007). These findings reveal- inhibition of biofilm formation by the LMWF of FBS or
human serum, at least in part, is due to inhibition of expression of biofilm-related genes.
Therefore, biofilm formation in vivo may be “selected for” (possibly by immune pressure
and sheer forces) rather than “induced” at the level of transcription. It is possible that S.
aureus exhibits the planktonic mode of growth in vivo to maximize its growth potential in
a nutrient-rich environment. The few bacteria that happen to adhere to the device would
have a selective advantage over the planktonic population, which would be killed by
immune defenses. Serum-mediated inhibition of biofilm formation may represent a
previously uncharacterized aspect of host innate immunity that targets the expression of a
key bacterial virulence factor: the ability to establish a resistant biofilm.
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CHAPTER 4
The effect of Catheter Lock Solutions on Staphylococcus aureus biofilm
formation; A strain dependent phenomenon

Introduction
Staphylococcus aureus is a leading cause of nosocomial infections and of
bloodstream infections (BSIs) associated with contaminated intravenous catheters.
Despite recent reductions in rates of central-line associated BSIs, catheter-associated
infections remain a leading cause of healthcare-associated infection (CDC, 2011).
Catheter-associated BSIs increase mortality rates, prolong patient stay, and increase
healthcare costs (Hugonnet, Sax et al., 2004). An important virulence factor in such
infections, especially S. aureus, is the bacterium’s ability to adhere to and form a biofilm
on the surface of the catheter.
Bacterial biofilms are communities in which intercellular bonds enforced by
polymeric compounds, and intercellular communication mediated by signaling
molecules, result in a bastion that is sheltered from sheer forces, antimicrobial agents, and
host immune components. Consequently, biofilm-related infections are very difficult to
treat therapeutically, and while antibiotics may eradicate the BSIs and temporarily relieve
the clinical signs of the infection, the biofilms often persist and act as a nidus for
relapsing infection (Hall-Stoodley, Costerton et al., 2004). Recent guidelines for
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prevention and treatment of catheter-related infections propose the use of intraluminal
antimicrobial lock solutions or catheter lock solutions (CLS) (Mermel, Allon et al., 2009;
O'Grady, Alexander et al., 2002; Raad and Hanna, 2002).
Heparin has traditionally been used to lock catheter lumens during interdialytic
periods. The use of heparin in lock solutions is safe and well tolerated, though it does not
help to prevent or treat central venous catheter (CVC)-related infections (Bestul and
Vandenbussche, 2005). This finding might be related in part to the fact that heparin alone
does not have any innate antimicrobial activity (Capdevila, Gavaldà et al., 2001).
However, recently, the use of heparin in lock solutions has been associated with some
risk factors including heparin-induced thrombocytopenia and thrombosis (Arepally and
Cines, 1998). Moreover, several investigators recently reported that heparin augments S.
aureus biofilm formation on catheter surfaces (Shanks, Sargent et al., 2006; Shanks,
Donegan et al., 2005) possibly mediated by the production of heparin-binding proteins by
the bacteria (Fallgren, Utt et al., 2001; Liang, Ascencio et al., 1992). Thus, heparin may
actually contribute to the incidence of catheter-related infections.
Therefore, as heparin alternatives, chelators such as trisodium citrate (NaCi),
Ethylenediaminetetraacetic acid (EDTA), and Ethylene glycol-bis(2-aminoethylether)N,N,N′,N′-tetraacetic acid (EGTA) have come into use as critical components of CLS.
These compounds have significant advantages providing three necessary and important
functions: an anticoagulant effect, an antibiofilm effect, and a synergistic antimicrobial
effect (Banin, Brady et al., 2006; Percival, Kite et al., 2005; Shanks, Sargent et al., 2006).
Metallic cations such as calcium (Ca2+), and magnesium (Mg2+) play an important role in
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microbial adherence, biofilm formation and bacterial growth. These divalent cations can
stimulate cell-cell adhesion and aggregation through their interactions with cell wall
teichoic acids (Dunne and Burd, 1992; Sarkisova, Patrauchan et al., 2005). Therefore
removal of free cations from the milieu, via these chemical chelators, reduces
intercellular adhesion and biofilm formation. Furthermore, chelating agents can reduce
biofilm formation by inhibiting the production of the staphylococcal polysaccharide
intercellular adhesin or poly-N-acetylglucosamine (PIA or PNAG) encoded by the ica
operon (Juda, Paprota et al., 2008; Ozerdem Akpolat, Elci et al., 2003). However, S.
aureus has many components, in addition to PNAG, that can contribute to adhesion and
biofilm formation.
The surface of S. aureus is coated with a variety of adhesins that are capable of
binding different host proteins present in plasma and/or the extracellular matrix. In some
cases these adhesins can also mediate bonds between bacterial cells (Corrigan, Rigby et
al., 2007; Cucarella, Tormo et al., 2002). There are at least 28 different S. aureus proteins
that promote the binding to 18 different host proteins (Clarke and Foster, 2006). Adhesins
that mediate such binding to host extracellular matrix proteins are termed MSCRAMMs.
S. aureus can express 4 distinct fibrinogen-binding MSCRAMMs: clumping factors A
and B (ClfA and ClfB) (Ni Eidhin, Perkins et al., 1998) and the fibronectin binding
proteins FnbA and FnbB, which bind to fibronectin and fibrinogen (Wann, Gurusiddappa
et al., 2000). Insertion of indwelling devices including artificial heart valves, pacemakers,
and catheters causes them to be immediately coated with blood components including
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fibrinogen and fibronectin and subsequently serve as efficient substrates for S. aureus
binding.
The effects of NaCi and other chelators on biofilm formation have not been fully
defined and we therefore designed this study to examine their effects. NaCi at low
concentrations has been shown to positively affect biofilm formation, not through its
chelating activity, but rather by acting as a tricarboxylic acid cycle intermediate (Shanks,
Meehl et al., 2008; Shanks, Sargent et al., 2006). Therefore we also investigated the
effect of EGTA. This study aimed to highlight the differences that exist between S.
aureus strains that vary dramatically in their ability to form biofilms in the presence of
chelating agents. Of clinical relevance, these results suggest that chelating agents in
catheter lock solutions may actually augment, rather than inhibit biofilm formation in
certain strains of S. aureus and suggest that a method to monitor their response to the
solutions may be necessary.

Results
Chelators exert different effects on biofilm formation in different strains
To gain some perspective on the effect of chelators (EGTA and NaCi) on S.
aureus biofilm formation, assays were performed using various laboratory strains. Strain
SA113 (ATCC 35556), derived from laboratory strain NCTC8325, is a proficient biofilm
producing type strain. To determine the minimum biofilm inhibition concentration,
bacteria were inoculated in TSBG with varying concentrations of EGTA ranging from 50
– 1.6 mM (Figure 8A). Biofilm formation was observed to decrease in a concentration
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dependent manner with complete ablation of any detectable biofilm by 12.5 mM. To
confirm that this chelator concentration was specifically inhibiting biofilm formation and
not just preventing growth, we analyzed both planktonic growth and biofilm formation
(Figure 8B). We found that 12.5 mM EGTA and 12.5 mM NaCi were sub-inhibitory and
allowed planktonic growth to occur (Figure 8B, blue bars) but completely ablated
biofilm formation (Figure 8B, red bars P<0.0001). Using the QuantiChrom™ Calcium
Assay kit we quantified free calcium levels within TSBG and TSBG containing EGTA.
The kit contains a phenolsulphonephthalein dye, which when complexed with free Ca2+
forms a very stable blue color. The intensity of the color, as measured by a
spectrophotometer at A612 nm, is directly proportional to the calcium concentration in the
sample. TSBG was observed to contain 4.2 mM Ca2+ while free Ca2+ was not detectable
by the assay with TSBG containing 12.5 mM EGTA. Postulating a role for free Ca2+ in
supporting biofilm formation within strain SA113, the addition of Ca2+ individually or in
concert with either EGTA or NaCi restored biofilm formation (Figure 8B).
While biofilm assays performed above confirmed the inhibitory effects of EGTA
and NaCi on SA113 biofilms we reconfirmed these results using a Live/Dead BacLight™
stain kit (Figure 9). SA113 were grown for biofilms within 6-well plates. Plates were
incubated for 18 h at 37 °C and thereafter washed away for non-adherent bacteria and
stained with SYTO® 9 and propidium iodide before confocal microscopy was performed.
Green-fluorescent SYTO® 9 stain when used alone labels both live and dead bacteria. In
contrast, propidium iodide penetrates only bacteria with damaged membranes, masking
SYTO® 9 fluorescence when both dyes are present. Thus, live bacteria with intact
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Figure 8. 12.5 mM EGTA or NaCi effectively inhibits SA113 biofilm formation. (A)
Strain SA113 was grown in TSBG supplemented with increasing concentrations of
EGTA ranging from 50 – 1.6 mM in a 96-well microtiter plates and the plate was
incubated for 18 h at 37 °C. The wells were washed for non-adherent bacteria, stained
with safranin, imaged and quantified at A415nm. (B) Strain SA113 was grown in TSBG
alone or supplemented with 12.5 mM CaCl2, 12.5 mM EGTA, 12.5 mM NaCi, 12.5 mM
CaCl2 + 12.5 mM EGTA, or 12.5mM CaCl2 + 12.5mM NaCi in 96-well microtiter plates.
The wells were either resuspended to determine growth (A595) or washed to remove nonadherent bacteria and stained with safranin to gauge biofilm formation. Plates were
scanned using a flatbed scanner (right) and shown here to represent technical duplicates
from one representative plate. Safranin stain was dissolved in acetic acid and quantified
at A415nm. Quantification of growth at A595 (blue bars) versus biofilm formation at A415nm
(red bars) under the respective conditions within the respective media condition is shown.
**P<0.0001 as determined by Student’s t-test.
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Figure 9. Confocal microscopy confirms an ablated biofilm phenotype within
EGTA. SA113 was grown for biofilms within 6 well plates in TSBG + 12.5 mM Ca2+
(calcium replete) or 12.5 mM EGTA (calcium deplete) or the two in concert with one
another- TSBG + 12.5 mM Ca2+ + 12.5 mM EGTA (calcium reconstituted) and stained
with Live/Dead BacLight™ stain and analyzed by confocal laser scanning microscopy.
The large panels are a top-down view of the biofilm. The right panels are a side view of
an x-axis section and the top panels are a side view of the y-axis section. Green color
indicates viable bacteria while the red color or yellow (red and green co-localized)
indicates dead bacteria.
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membranes fluoresce green, while dead bacteria with damaged membranes fluoresce red.
We observed under Ca2+ replete or when reconstituted with EGTA, robust biofilms were
established with a high density of green fluorescence throughout the architecture. In
contrast SA113 under Ca2+ deplete conditions were strongly inhibited for biofilms and
the few cells that remained attached were non viable.
To extend our findings, we analyzed biofilm formation under similar chelated
conditions using Newman, which apart from SA113 was previously observed (Chapter 3)
to repress biofilm formation within serum, and compare it to its genetically related
variant- strain 10833 (Figure 10). The biofilm phenotype was significantly inhibited by
EGTA and NaCi in Newman (Figure 10), similar to what was observed with strain
SA113 (Figure 8B, 9). However, in strain 10833, EGTA and NaCi actually increased
biofilm formation relative to the diminished or ablated biofilms observed with Newman
(Figure 10, P<0.0001) or SA113 (Figure 8B, 9).

Increased clumping within S. aureus strain 10833
Strains 10833 (ATCC 25904) and Newman, a throat swab isolate, are two closely related
strains, as previously determined by MLST and spa typing (Duthie and Lorenz, 1952;
Grundmeier, Hussain et al., 2004; Kropec, Maira-Litran et al., 2005; personal
communication). We hypothesized that because they are genetically similar, the
diametrically opposed phenotypes expressed by these two strains in the presence of
chelators could have a relatively straightforward molecular basis. Strong clumping factor
activity of 10833 has been previously documented (Duthie and Lorenz, 1952). We
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Figure 10. Different strains of S. aureus exert diametric effects for biofilm formation
within chelating agents. Strains 10833 and Newman were grown for biofilms in TSBG
alone or supplemented with 12.5 mM EGTA or 12.5 mM NaCi within 96-well
polystyrene microtiter plates. Plates were incubated statically at 37 °C for 18 h.
Thereafter, the wells were washed for their media and non-adherent cells, and stained for
any detectable biofilms using safranin. Biofilms were imaged and then quantified using
33% acetic acid and measured at A415nm (red bars). Growth, within the individual media
conditions, was also assessed by resuspending the cells, prior to washing, and quantified
at A595nm (blue bars). Results are and accumulation of three biologic replicates each with
five technical replicates. **P<0.0001 as determined by Student’s t-test.
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therefore compared the clumping activity of the two strains in the absence and presence
of 12.5 mM EGTA (Figure 11). When diluted cultures of bacteria were inoculated into
media and incubated overnight, 10833, within the EGTA chelated media aggregated and
fell out of solution (clumped). Newman, on the other hand, did not exhibit any significant
clumping and continued to remain dispersed throughout the volume of the liquid. Neither
strain was observed to show any signs of clumping when cultured with TSBG alone.
To further elucidate the increased clumping effect displayed by 10833 we
performed scanning electron microscopy (SEM) on biofilms produced by 10833 in TSBG
or added 12.5 mM EGTA (Figure 12). Biofilms produced by this strain, in either media
condition, were grown on clear glass coverslips, washed to remove non-adherent bacteria
and negatively stained with phosphotungstic acid before scanning electron microscopy
was performed. Microscopy clearly showed a disparity between the biofilms produced by
this strain, with a significant amount of an extracellular surface-associated material when
this strain is grown in EGTA (Red arrows) versus that in TSBG alone.

10833 displays increased adherence to catheters in the presence of EGTA
To test the hypothesis that chelators like EGTA may not effectively inhibit
biofilm formation on catheters by all S. aureus strains, we quantified adherence to
catheter tubing. For this purpose, bacteria (10833 or Newman) were diluted in test tubes
with either TSBG or media supplemented with 12.5 mM EGTA and a small piece of
catheter tubing was added to each tube and incubated for 18 h at 37 °C without shaking.
The catheters were sterilely removed, washed for non-adherent bacteria, sonicated and
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Figure 11. 10833 exhibits a clumping phenotype within chelated media. Strains
10833 and Newman were incubated, without shaking, in TSBG alone or supplemented
with 12.5 mM EGTA at 37 °C for 18 h. The tubes were then briefly vortexed and then
imaged. The red circle highlights the observed aggregation and clumping.
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Figure 12. Scanning electron microscopy of 10833 biofilms. Overnight cultures of
strain 10833 were grown for biofilms on clear glass coverslips placed within 6-well
plates. Biofilms were grown in TSBG or TSBG + 12.5 mM EGTA and allowed to
incubate at 37 °C for 18 h. The biofilms produced on the coverslips were carefully
washed for non-adherent bacteria and then negatively stained with phosphotungstic acid.
Scanning electron microscopy revealed large clumps of adherent bacteria in 12.5 mM
EGTA. Associated with these aggregations was a significant amount of a surfaceassociated extracellular material (red arrows) that was not as pronounced with biofilms
produced within TSBG alone. These micrographs are single image representations found
throughout the well. (Magnification 7000X).
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plated for cfu counts on TSA plates (Figure 13). Adherence of strain Newman to catheter
tubing was inhibited by EGTA; however, a 6-fold increase in adherence was observed for
10833 in the presence of 12.5 mM EGTA relative to the TSBG control. The high
concentration of EGTA did not decrease cell viability, therefore, this assay additionally
confirmed the viability of 10833 in EGTA.

Increase in biofilm formation by 10833 in EGTA is not due to an increase in PNAG
S. aureus biofilms can be composed of various components including
polysaccharides like PNAG (O’Gara, 2007), proteinaceous adhesins (Corrigan, Rigby et
al., 2007; Rohde, Burandt et al., 2007) and/or eDNA (Rice, Mann et al., 2007). Each of
these components may be present in varying amounts or absent completely, depending on
the strain background and the growth conditions. The ica locus of S. aureus encodes the
exopolysaccharide PNAG that has been previously shown to contribute to biofilm
formation within this species (Cramton, Gerke et al., 1999). Strains likes SA113 and
MN8, a clinical isolate from a nonmenstrual toxic shock syndrome case (Schlievert and
Blomster, 1983), produce copious amounts of PNAG that aid in biofilm formation
(Cramton, Gerke et al., 1999; Jefferson, Pier et al., 2004). Therefore, we wanted to
investigate the relative contribution of PNAG within 10833 biofilms established in the
chelating conditions (Figure 14A). Standardized amounts of overnight cultures of
bacteria were centrifuged to pellets (Surface-associated fraction) and the cells were
resuspended in 0.5 M EDTA. The supernatant from the pelleted cells (Secreted fraction)
and the Surface-associated fraction were boiled, diluted in 1X PBS, and blotted onto a
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Figure 13. 10833 exhibited greater adherence to catheter tubing in the presence of
EGTA. Bacteria were diluted in test tubes with either TSBG (dark grey bars) or TSBG +
12.5 mM EGTA (light grey bars) along with a ~2 cm piece of vialon based catheter
tubing. The tubes were incubated for 18 h at 37 °C without shaking. The catheters were
sterilely removed, washed to remove non-adherent bacteria, sonicated and plated for cfu
counts on TSA plates. **P<0.0001 as determined by Student’s t-test.
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nitrocellulose membrane. The membranes were then dried, blocked with BSA, and probed
with α-PNAG antibody followed by a α-goat HRP labeled secondary antibody (Figure
14A). Strain 10833 produced only a small amount of PNAG when grown in TSBG,
however, the strain showed very little, if any, detectable polysaccharide production when
grown in EGTA.
We confirmed these results by assessing the transcript levels of the icaA and icaR
genes by isolating total RNA from 10833 grown in TSBG or added 12.5 mM EGTA or
12.5 mM NaCi and performing quantitative realtime RT-PCR analysis (Figure 14B). The
icaA gene is the first gene of the intercellular adhesin icaADBC operon and functions as
an N-acetylglucosaminyltransferase and, using UDP-N-acetylglucosamine as its
substrate, facilitates the synthesis of 10-20-mers of N-acetylglucosamine (Gerke, Kraft et
al., 1998). IcaR is as a trans-acting transcriptional repressor of the ica operon and is
located immediately upstream of icaADBC operon. Figure 14B shows an approximately
3-fold increase in expression of icaR when 10833 was cultured in either 12.5 mM EGTA
or NaCi. In addition, there was a simultaneous repression of the icaA transcript with each
of these chelating conditions. This would suggest that the increase in biofilm formation
by 10833 in EGTA or NaCi is not due to the production of PNAG. Identifying neither
eDNA nor PNAG to play a role within 10833 biofilms within chelating agents would
suggest a role for proteinaceous adhesins mediating this phenotype.

Chelators lead to an increase in the level of Clumping factor B transcript
The two primary staphylococcal factors associated with clumping are clumping
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Figure 14. 10833 biofilms in EGTA is not due to increased PNAG production. (A)
Overnight cultures of wildtype strain 10833 was grown overnight in either TSBG or
media with 12.5 mM EGTA. Cultures were centrifuged to pellets and resuspended in 0.5
M EDTA (Surface-associated). The supernatants from the pellets (Secreted) and the
Surface-associated fractions were boiled to extract PNAG, diluted 1:10 within 1X PBS,
and blotted onto a nitrocellulose membrane. The membranes were probed with an αPNAG antibody and an HRP-labeled secondary antibody before being analyzed by x-ray
film. (B) RNA was extracted from 10833 grown in TSBG, TSBG + 12.5 mM EGTA or
TSBG + 12.5mM NaCi during mid-log phase of growth. Transcript levels for the icaA
and icaR genes were analyzed by quantitative realtime RT-PCR. The individual genes
were normalized to 16S rRNA and the relative fold expression with respect to TSBG
alone is shown. **P<0.0001 as determined by Student’s t-test.
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factors A (ClfA) and B (ClfB). Previous reports suggest that ClfA and ClfB-mediated
clumping requires the presence of fibrinogen (Ni Eidhin, Perkins et al., 1998); however,
we hypothesized that in the presence of a chelating agent these factors could induce
clumping in the absence of fibrinogen. We therefore investigated the relative expression
of the clumping factor genes clfA and clfB when bacterial cultures were incubated in
TSBG containing 12.5 mM EGTA or 12.5 mM NaCi relative to TSBG alone (Figure 15).
The levels of clfA transcript were unchanged by EGTA in either strain. However, in
Newman, clfB transcript levels were lower in the presence of EGTA but were increased
3-fold in the presence of EGTA in strain 10833. Additionally, we observed a 1.5-fold
increase in clfB transcript levels in 10833 in 12.5 mM NaCi, whereas clfB transcript
levels were severely decreased for Newman cultures grown in NaCi. In sum, the
expression of clfB was negatively regulated in the presence of EGTA or NaCi in Newman
but positively regulated by the chelators in 10833.

Gene sequence and transcriptional start site is conserved between 10833 and
Newman.
We next sought to determine whether the difference in clfB expression in strains
10833 and Newman was due to a mutation in the gene or promoter. For this purpose, we
sequenced the clfB gene and the upstream region (Figure 16). The clfB gene from 10833
was identical to Newman except for the presence of additional SD repeats, only
lengthening the protein, and the upstream promoter regions were 100% identical to the
previously published Newman sequence (Baba, Bae et al., 2008). We also determined the
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Figure 15. Expression of clumping factor B (clfB) in the presence of NaCi and
EGTA. Total RNA was isolated from strains 10833 and Newman that were grown in
TSBG, TSBG + 12.5 mM EGTA, and TSBG + 12.5 mM NaCi during mid-log phase of
growth. Transcript levels of the clumping factor gene clfB were analyzed by realtime RTPCR. Individual genes were normalized to 16S rRNA and the relative fold difference is
shown with respect to TSBG. Black bars represent relative gene expression by strain
10833 while the grey bars are representative of Newman. **P<0.0001 as determined by
Student’s t-test.
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transcriptional start site using 5’-RACE analysis and observed transcription started at the
same nucleotide in both strains.

Clumping factor B, clfB is required for EGTA-induced biofilm formation in 10833
To further investigate the role of clumping factor B in the differential effect of
EGTA on biofilm formation in strains Newman and 10833, isogenic clfB deletion
mutants were made and biofilm assays were performed (Figure 17). Deletion of clfB in
strain 10833 abrogated biofilm formation significantly (Figure 17B, P<0.0001) when the
strains were grown in 12.5 mM EGTA but did not significantly affect biofilm formation
in the absence of EGTA. Quantitative realtime RT-PCR demonstrated that in strains
complemented in trans with clfB-pCL15, 1 mM IPTG restored clfB transcript levels to
that of the parental strains (Figure 17A). Complementation of clfB gene expression
restored biofilm formation, of 10833 in EGTA, to that of wildtype (Figure 17C, black
arrows). In strain Newman, biofilm formation in TSBG was unaffected by the deletion,
but the weak biofilm formed in the presence of EGTA was further reduced by the clfB
mutation (Figure 17B, P<0.0001). Complementation of the gene restored biofilm levels
to that observed with the wildtype strain in the presence of EGTA. Together these results
suggest that biofilms formed in the presence of EGTA are ClfB-dependent and that ClfB
results in the production of a thicker biofilm in 10833 than in Newman.

ClfB is required for increased biofilm formation in EGTA
The data thus far has pointed towards ClfB playing a critical role in contributing
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Figure 16. Transcriptional start sites for clfB are identical in 10833 and Newman.
Schematic representation of the clfB gene displaying transcriptional start site (+1) for
strains 10833 and Newman as determined by 5’-RACE analysis. The translational start
site is underlined. The predicted -10 and -35 promoter-binding sites as determined
bioinformatically using the SoftBerry promoter analysis program, are also shown.
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Figure 16. Deletion of clfB abrogates biofilm formation in the presence of EGTA.
(A). Overnight cultures of strains 10833, Newman, and their respective isogenic and
complementation mutants were diluted in fresh TSBG and total RNA was isolated from
cultures grown until mid-logarithmic phase. Quantitative realtime RT-PCR analysis was
performed to determine the concentration of IPTG (0 mM, 1 mM, or 5 mM) required to
restore clfB transcripts levels, within the complementation mutants, to that of wildtype. S.
aureus strain 10833 (B), Newman (C) and their isogenic clfB deletion and
complementation mutant derivatives were grown in 96-well polystyrene plates in TSBG
(dark grey bars) or TSBG + 12.5 mM EGTA (light grey bars) and assessed for biofilm
formation. Biofilms were stained for visualization (right) and quantified at A415nm (left).
The complementation mutants were induced (I) with 1 mM IPTG or remained uninduced
(U). The black arrows point towards the visual differences between the WT, deletion
mutant, and the induced complemented strain. *P<0.001, **P<0.0001 as determined by
Student’s t-test.
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to the increased biofilms observed by lab strains within chelating agents like EGTA and
NaCi. S. aureus expresses a large number of MSCRAMM proteins that can bind
specifically to different components of the host extracellular matrix. Among these
proteins, four are known to bind fibrinogen. Apart from the fibrinogen-binding clumping
factor proteins ClfA and ClfB, recently, the fibronectin binding protein FnbA has also
been implicated in a similar adherent capacity (Wann, Gurusiddappa et al., 2000). Figure
18A schematically describes the high degree of structural and organization similarity that
exists between ClfA, ClfB and FnbA. The ‘A’ or ligand-binding domain of ClfA and
ClfB facilitates fibrinogen binding (Perkins, Walsh et al., 2001) and, we hypothesize this
domain within ClfB to contribute to intercellular aggregation and biofilm formation
observed within strains like 10833. Therefore, to rule out the possibility these other
MSCRAMMs were playing a role with increased biofilm formation in chelated media we
acquired a series of transposon insertion mutants within these genes.
In an effort to enhance the research capabilities of the staphylococcal research
community, the Center for Staphylococcal Research (CSR) at the University of Nebraska
Medical Center has generated a collection of sequence-defined transposon (Tn) insertion
mutants within the non-essential genes of S. aureus strain USA300 JE2. This strain was
derived from a well-characterized CA-MRSA strain isolated from the Los Angeles
County jail- USA300 LAC (Kennedy, Otto et al., 2008). Although the genome of this
strain has not been sequenced, only 11 SNPs (single nucleotide polymorphisms) were
detected between this strain and the sequenced strain USA300 FPR3757 (Kennedy, Otto
et al., 2008). This Nebraska Tn Mutant Library was constructed using bursa aurealis, a
98

mariner-based transposon (Bae, Glass et al., 2008). The mutants that revealed a
transposon insertion within the first third of a gene were robotically re-arrayed into a 96well format and then resequenced to verify the identify of each mutant.
Using standard biofilm assays, we compared the wildtype strain USA300 JE2 to a
series of transposon insertion mutants within genes including clfB (NE391), clfA
(NE543), fnbA (NE186), and another undefined putative fibrinogen/fibronectin binding
protein gene (NE551) (Figure 18B). This assay revealed two very interesting findingsThe wildtype USA300 JE2 strain, similar to 10833, showed a severe increase in the
biofilm phenotype when grown under the chelating condition (EGTA). Secondly, the
NE391 (∆clfB) strain failed to form a biofilm in EGTA. All other mutants revealed high
biofilm mass similar to the wildtype when cultured within EGTA. This directly
implicates ClfB as the sole determinant associated with increased biofilms under
chelating agents. Additionally, the use of this clfB transposon mutant serves as
independent confirmation of our own chromosomal deletion phenotype, generated within
10833 and Newman, that reveal loss and further reduction of biofilms compared to their
respective wildtype strains when grown under similar chelating conditions.

Effect of chelators on biofilm formation in cardiac device-associated isolates
To identify whether this phenomenon; chelator-mediated augmentation of biofilm
formation within strains like 10833 and USA300 JE2, was a common occurrence with
clinical strains, we next tested a panel of clinical isolates from the bloodstream of patients
with cardiac device-associated infections (provided by Dr. Vance Fowler, Duke
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Figure 18. ClfB promotes biofilm formation within chelated media. (A) Schematic
representation and comparison between the ClfB, ClfA and FnbA MSCRAMMs. S:
signal sequence; A: unique N-terminal ligand binding domain, binds fibrinogen (ClfA
and ClfB); B, C, and D: homologous repeats of unknown function; SD Repeat Region:
serine-aspartate dipeptide repeat region; W, wall-spanning region (WR: Octapeptide
repeat, WC: Conserved repeat); M: membrane-spanning domain. The LPETG motif, is
involved in anchoring the proteins to the cell wall peptidoglycan (all three proteins) and
the SLAVA motif is a putative metalloprotease cleavage site (only ClfA and ClfB). The
percentage residue identity between the respective regions of ClfA and ClfB proteins is
shown. (B) S. aureus strain USA300 JE2 and the transposon insertion mutants NE391
(∆clfB), NE543 (∆clfA), NE186 (∆fnbA), and NE551 (undefined fibrinogen/fibronectin
binding protein) were grown in TSBG (dark grey bars) or TSBG + 12.5 mM EGTA (light
grey bars) within individual wells of a 96-well polystyrene plate. Biofilms were stained
for visualization (right) and quantified at A415nm (left). **P<0.0001 as determined by
Student’s t-test.
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University, Durham, NC) (Table 3). Out of 27 isolates, biofilm formation was inhibited
(by at least 25%) by both chelators in 5, was not significantly affected by the chelators in
3, and was augmented by both chelators in 8. The remaining strains exhibited variable
responses to NaCi and EGTA. These results demonstrated that, while sub-inhibitory
concentrations of EGTA and NaCi inhibit the biofilm phenotype in certain strains of S.
aureus, they actually stimulate the biofilm phenotype in others.
To further add weight to our growing hypothesis that ClfB was playing a
dominant effect in strains that exhibited augmented biofilm phenotypes within chelated
media, we phage transduced the clfB chromosomal deletion into two clinical isolates, VF
Strains 19 and 24, that were observed to show increased biofilms within EGTA and NaCi
and performed biofilm assays (Table 3, Figure 19). Deletion of clfB from Strain 19
showed a significant decrease, 73% and 46% in EGTA and NaCi respectively
(P<0.0001), in relation to the wildtype controls. Likewise, clfB mutants of Strain 24
showed similar trends- 98% and 48% decrease in biofilms in EGTA and NaCi
(P<0.0001). We therefore concluded that, there exist, naturally occurring, clinical strains
of S. aureus that are refractory to the inhibitory effects of such chelating agents and
augment biofilm formation within sub-inhibitory concentrations of these chelators.
Furthermore, ClfB appears to be the mediator of this effect, at least in the strains that we
tested in this study. Resistance of biofilm formation to the chelating agents could
potentially account for the rapidly increasing numbers attributing S. aureus as one
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Table 3. Effect of 12.5 mM EGTA or 12.5 mM NaCi on biofilm formation in 27 cardiac
device-associated isolates

VF Strain #

% Biofilm in 12.5 mM

% Biofilm in 12.5 mM

EGTA relative to TSBG

NaCi relative to TSBG

Strain 1DOWN

29.78 ± 0.07

31.75 ± 0.04

Strain 2 DOWN

21.06 ± 0.17

74.33 ± 0.04

Strain 3 UP

125.23 ± 0.06

163.48 ± 0.04

Strain 4

59.25 ± 0.23

173.68 ± 0.07

Strain 5 UP

161.67 ± 0.05

174.34 ± 0.06

Strain 6

101.70 ± 0.03

82.23 ± 0.04

Strain 7

103.96 ± 0.04

79.01 ± 0.03

Strain 8

132.61 ± 0.05

63.27 ± 0.06

Strain 9 UP

130.58 ± 0.03

140.28 ± 0.06

Strain 10 UP

126.37 ± 0.04

145.30 ± 0.04

Strain 11

134.86 ± 0.06

80.62 ± 0.06

Strain 12 DOWN

6.95 ± 0.01

32.27 ± 0.02

Strain 13

54.26 ± 0.14

92.15 ± 0.10

Strain 14

117.36 ± 0.04

91.35 ± 0.06

Strain 15

209.29 ± 0.10

105.01 ± 0.05

Strain 16

125.52 ± 0.03

90.60 ± 0.04

Strain 17

127.56 ± 0.06

97.27 ± 0.07
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UP

Strain 18

113.92 ± 0.02

60.38 ± 0.04

Strain 19UP

126.88 ± 0.06

136.82 ± 0.07

Strain 20

203.33 ± 0.07

106.29 ± 0.03

Strain 21 DOWN

16.49 ± 0.08

45.24 ± 0.03

Strain 22 DOWN

7.92 ± 0.00

30.65 ± 0.02

Strain 23UP

432.11 ± 0.16

243.17 ± 0.06

Strain 24 UP

314.24 ± 0.08

140.09 ± 0.05

Strain 25 UP

757.19 ± 0.06

162.41 ± 0.02

Strain 26

73.16 ± 0.01

180.31 ± 0.01

Strain 27

115.06 ± 0.07

126.01 ± 0.07

Strains- observed to showed significant increase (≥ 25% relative to TSBG) in biofilm

formation within EGTA and NaCi relative to their TSBG control (P<0.0001)
DOWN

Strains- significantly decreased in biofilm formation in EGTA and NaCi

(P<0.0001)
Underlined VF Strains 19 and 24 were used to assess the role for ClfB in promoting
increased biofilms within the two chelating conditions (Figure 19)
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Figure 19. Biofilms produced by VF Strains 19 and 24 in EGTA and NaCi are ClfBdependent. Two clinical isolates VF Strain 19 and Strain 24, identified to exhibit
increased biofilm within EGTA and NaCi (Table 3) were compared to their, phage
transduced, clfB deletion mutants for growth (A595nm, Blue bars) and biofilm formation
(A415nm, Red bars) within TSBG, TSBG + 12.5 mM EGTA, and TSBG + 12.5mM NaCi.
Bacteria were inoculated into wells of a 96-well polystyrene plate and incubated at 37 °C
for 18 h. Growth was assessed prior to biofilm staining. Biofilms were washed, stained
for visualization with safranin (right) and quantified at A415nm (left). **P<0.0001 as
determined by Student’s t-test.
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of the leading causes of catheter-related BSIs. These results demonstrate prevalence of a
subset of strains that exhibit chelator-mediated biofilm formation and this novel
phenomenon seems to be dependent on ClfB as the primary molecular determinant of
these biofilms.

α-ClfB antibody inhibits aggregation and clumping of 10833 and USA300 JE-2
Aggregation and clumping is an important phenotype exhibited by many bacteria
and this usually precedes successful biofilm formation. Various surface-associated
proteins of S. aureus have been implicated in intercellular aggregation leading to biofilm
formation. These include- S. aureus surface protein G (SasG) (Kuroda, Ito et al., 2008;
Corrigan, Rigby et al., 2007), S. aureus surface protein C (SasC) (Schroeder K, Jularic et
al., 2009) and extracellular adherence protein (Eap) (Thompson, Abraham et al., 2010).
To directly implicate ClfB in the aggregation and clumping phenotype, we employed the
use of a rabbit α-ClfB antibody (kindly provided by Dr. Gerald Pier, Harvard University,
Boston, MA). The antibody was generated against the A domain of ClfB that has been
implicated previously in binding to immobilized host matrix component fibrinogen
(Perkins, Walsh et al., 2001).
Overnight cultures of bacteria- 10833, Newman and USA300 JE2 and their
isogenic clfB chromosomal deletion or transposon insertion mutants, standardized to
ensure equal amount of bacteria, were inoculated into test tubes with fresh media i.e.
TSBG or TSBG + 12.5 mM EGTA containing 4.0 µg/mL α-ClfB antibody, pre-immune
antibody or No antibody. The tubes were incubated at 4 °C for 2 h, to ensure binding of
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the antibody and thereafter transferred to 37 °C to incubate, without shaking, for 18 h.
Tubes were removed, gently vortexed and observed for clumping and aggregation
(Figure 20). In the absence of any antibody 10833 was observed to clump in EGTA, as
previously observed in Figure 11. However, the addition of the α-ClfB antibody
prevented this strain from clumping. The use of the rabbit pre-immune sera controls for
the presence of any specific or non-specific α-staphylococcal antibody that would inhibit
the strain from clumping. The pre-immune sera, similar to the no antibody treatment,
permitted 10833 to clump in EGTA. The isogenic clfB mutant strain showed absence of
any clumping in any of the conditions tested. Newman was previously observed, in
Figure 11, to show no sign of clumping in either chelated or non-chelated media in the
absence of any antibody. This was confirmed in this assay (Figure 20). Thus, the
presence of the α-ClfB antibody also showed no signs of clumping in EGTA. Finally,
strain USA300 JE2 showed similar trends as 10833, clumping in the absence of the
antibody in EGTA and loss of this phenotype was with the addition of the α-ClfB
antibody. The control strain NE391, displayed no apparent clumping under any condition
tested. This data suggests a direct impact ClfB plays in promoting bacterial aggregation
and clumping in chelated solutions, especially within strains like 10833 and USA300 JE2
and that this phenotype can be abrogated with the addition of the α-ClfB antibody.

α-ClfB antibody inhibits biofilm formation in 10833 and USA300 JE-2
To confirm the role for ClfB in biofilm formation, we utilized the α-ClfB
antibody and analyzed its effects on biofilm formation in strains 10833 and USA300 JE2
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Figure 20. 10833 and USA300 JE2 lose their clumping phenotype in EGTA with the
addition of α-ClfB antibody. Strains 10833, Newman and USA300 JE2 were grown in
the presence of TSBG or TSBG + 12.5 mM EGTA and 4.0 µg/mL of either the α-ClfB
antibody, the rabbit pre-immune sera or absence of any added antibody. The cultures
were added to test tubes and first allowed to incubate at 4 °C for 2 h to promote antibody
binding to the cells and thereafter transferred to 37 °C for 18 h, without shaking. The
tubes were briefly vortexed and then imaged. The red circle highlights the aggregative
and clumped phenotype observed with strains. Control strains, including the two 10833
and Newman isogenic clfB chromosomal mutants and the NE391 transposon insertion
mutant, were also tested.
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within chelated media. Overnight cultures of wildtype bacteria- 10833, Newman, and
USA300 JE2 were diluted to an OD600 of 0.015 and added to fresh media, either TSBG or
TSBG + 12.5 mM EGTA along with varying concentrations of α-ClfB antibody, preimmune antibody (0.5 – 16.0 µg/mL) and compared biofilms formed in the absence of
any antibody. The bacteria were inoculated into individual wells of a 96-well plate and
incubated first for 2 h at 4 °C and then transferred to the 37 °C for 18 h. The wells were
washed with water, to remove non-adherent bacteria, and stained with safranin to
determine any detectable biofilm. The percent inhibition of biofilm was calculated using
the formula: [1- (Biofilm415nm (with antiserum) / Biofilm415nm (without antiserum)] ✕ 100 (Hussain,
Herrmann et al., 1997) (Figure 21).
Biofilm formation by 10833 in EGTA (Figure 21A) was decreased with
increasing concentrations of the α-ClfB antibody with concentrations greater than 4.0
µg/mL preventing any biofilm from being produced (P<0.0001). At high concentrations
of the antibody (≥4.0 µg/mL) a significant loss of biofilm, previously obtained with lower
concentrations (≤2.0 µg/mL), was observed (>65% inhibition, P<0.0001). To ensure high
concentrations of the inhibiting α-ClfB antibody did not detrimentally affect cell growth,
growth at A595nm was assessed (Figure 21A, green dots). The α-ClfB antibody did not
adversely affect growth of this strain within EGTA at any of the antibody concentrations
used. In contrast, biofilms produced by this strain in TSBG alone remained robust and
intact at every concentration of the α-ClfB antibody tested. The pre-immune control
antibody remained ineffective in inhibiting biofilms produced by this strain in TSBG or
EGTA. Strain Newman (Figure 21B) forms significant biofilms only in TSBG and thus
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Figure 21. Biofilm formation by 10833 and USA300 JE2 is inhibited in EGTA with
the addition of the α-ClfB antibody. Overnight cultures of 10883 (A), Newman (B),
and USA300 JE2 (C) were diluted in fresh TSBG or TSBG + 12.5 mM EGTA and
treated with varying concentrations of either α-ClfB antibody or rabbit pre-immune sera
(0.5 – 16.0 µg/mL) or absence of any added antibody and added to wells of a 96-well
polystyrene plate. The plates were incubated at 4 °C for 2 h to promote antibody binding
and thereafter moved to the 37 °C for 18 h. Non-adherent cells were removed by washing
with water and adherent bacteria were stained with safranin. Biofilms were quantified at
A415nm and the percent inhibition of biofilm formation was determined using the formula:
[1- (Biofilm415nm (with antiserum) / Biofilm415nm (without antiserum)] ✕ 100. The representative
biofilm images grown in either TSBG or supplemented EGTA treated with either α-ClfB
antibody or rabbit pre-immune sera are shown below the graphs. Growth (A595nm, green
dots) was assessed for 10833 and USA300 JE2 (within EGTA) and Neman (within
TSBG) in the presence of the α-ClfB antibody to ensure high concentrations of the
antisera did not affect growth. **P<0.0001 as determined by Student’s t-test.
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only this condition was tested. Biofilms produced by Newman in TSBG remained
unaffected and without any significant loss to the architecture in the presence of the αClfB antibody. Figure 21C shows the experiment performed with strain USA300 JE2.
Similar results as 10833 were observed, with significant inhibition of biofilm formation
in EGTA with ≥4.0 µg/mL α-ClfB antibody. Biofilms were significantly abrogated
(>60% decrease) at concentrations greater than 4.0 µg/mL (P<0.0001) when this strain
was grown in the presence of EGTA. In contrast, there no effect of the α-ClfB antibody
when USA300 JE2 was grown in TSBG, or in either media condition tested
supplemented with the pre-immune antibody. Results from Figure 20 and Figure 21
implicate ClfB, not only promoting clumping and aggregation within strains like 10833
and USA300 JE2 in chelated media but also confirm ClfB as playing a crucial role within
these biofilms.

ClfB protein is expressed during aggregative stationary growth
Using the α-ClfB antibody, we investigated the relative expression of the ClfB
protein across strains grown under the chelating condition. Overnight cultures of wildtype
and isogenic clfB mutant bacteria were diluted in TSBG or media supplemented with 12.5
mM EGTA and added to test tubes. The cells were incubated under static conditions for
18 h, collected by centrifugation, pellets were standardized by weight and total surface
protein extracted. The proteins were separated by SDS-PAGE, transferred to a PVDF
membrane, probed using the polyclonal IgG rabbit α-ClfB antibody followed by a
secondary goat α-rabbit HRP labeled antibody and developed using x-ray film.
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Western blotting is a common technique used to detect and quantify proteins in S.
aureus. However, protein A (Spa) secreted by 99% of S. aureus isolates (Goding, 1978)
interferes with such assays by binding to the Fc region of most mammalian IgGs. To
prevent interference Nguyen et al. demonstrated the use of increasing concentrations of
diethylpyrocarbonate (DEPC) to successfully inhibited the interaction of protein A with
the capturing antibody. Spa binding is mediated through an exposed histidine residue at
position 435 in mammalian IgG (Deisenhofer, 1981). DEPC was originally shown to
interfere with the binding of Spa to histidine-435 of mammalian IgG (Schroder, Nardella
et al., 1987), however, more recent data has identified other residues including lysine,
tyrosine, serine and threonine residues that can be modified by DEPC (Hnizda, Santrucek
et al., 2008; Mendoza and Vachet, 2008). After numerous blots, we determined 5 mM
DEPC along with 10% human serum, which naturally contains non-specific αstaphylococcal and α-Spa antibodies, supplemented to the primary α-ClfB antibody
inhibited enough of the nonspecific binding by protein A such that the ClfB protein could
be detected.
As shown in Figure 22, expression of the 150-kDa ClfB protein was much greater under
chelated conditions. There was absence of any protein production from the isogenic clfB
mutants under any condition tested. Wildtype Newman did not produce detectable levels
of the protein under any condition. Finally, strain USA300 JE2 showed high expression
of the protein when cultured with EGTA in relation to TSBG control. There were
moderate levels of expression from the NE543 (∆clfA) under both conditions and no
expression from the NE391 (∆clfB) mutant. This reconfirms our previous
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Figure 22. Western blot analysis of ClfB protein by S. aureus strains grown under
chelated versus non-chelated condition. S. aureus strains 10833, Newman, USA 300
JE2, and their isogenic chromosomal or tansposon insertion mutants were grown
stationarily for 18 h in tubes within TSBG or added 12.5 mM EGTA. Total surface
protein was extracted using 0.5 µg/mL of lysostaphin treatment and sonication and loaded
into each well of a 4-12% NuPAGE SDS PAGE gel. Proteins were separated on the
PAGE gel for 2 h at 200 V and then transferred to PVDF membranes for western blot
analysis. The proteins were blocked in 5% skim milk overnight and probed thereafter
with α–ClfB antibody (4.0 µg/mL). Molecular mass of ClfB (150kDa) is shown to the
right and left (black arrows).

118

119

observations (Figure 18B) that ClfB and not closely related ClfA or the other fibronectin
binding proteins promote chelator induced biofilm formation.

Discussion
Catheter-related bloodstream infections are a significant iatrogenic complication
associated with the use of implanted intravascular devices, and incidence increases
proportionally with the length of time that the catheter is left in place. Use of chelating
agents such as NaCi in CLS have been previously shown to disrupt the process of
bacterial adherence and biofilm formation on the synthetic surface, and can help prevent
catheter contamination (Banin, Brady et al., 2006; Shanks, Sargent et al., 2006).
However, catheter-related infections still occur, suggesting that bacteria can form
biofilms even in the presence of antibiofilm CLS. This study elucidated the prevalence of
certain strains of S. aureus that are adapted to becoming resistant to the antibiofilm
effects of chelating agents and the results suggest that in certain cases, sub-inhibitory
concentrations of the chelators could exacerbate the problem of biofilm formation.
We found that 12.5 mM EGTA and 12.5 mM NaCi were the minimum inhibitory
concentrations required to effectively inhibit biofilm formation in 2 out of 4 laboratory
strains (Newman and SA113) but augment it the others (10833 and USA300 JE2)
(Figures 8B, 10, 17B). Furthermore, while biofilm formation in 5 out of 27 cardiac
device-associated isolates was inhibited by both chelators, it was augmented by them in 8
suggesting that strains that cause biofilm-related infections may be more likely to
produce biofilms under a variety of conditions (Table 3). These two pieces of data
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combined reveal the innate variability that exists between the biofilm components of
various, clinical and laboratory, strains. The concentrations of the chelators used in this
study were sub-inhibitory, suggesting that they specifically affected the biofilm
phenotype. The concentration of NaCi used in this study was lower than the
concentrations in catheter lock solutions. However, sub-inhibitory doses would be
expected during dialysis as the CLS is removed from the catheter lumen.
NaCi has been shown to prevent biofilm formation but very low doses can augment
biofilm formation by serving as a TCA cycle intermediate (Shanks, Meehl et al., 2008;
Shanks, Sargent et al., 2006). Therefore, to circumvent this concern and to ensure the
results we observed were specifically due to metal ion chelation, we used EGTA in
addition to NaCi. Closely related strains Newman and 10833, the focus of this study,
were affected diametrically by both compounds, strongly suggesting that the effects were
directly related to the sequestration of metal cations, especially Ca2+. Many of the cardiac
device isolates exhibited increased biofilm formation in both EGTA and NaCi, however,
some were affected differently by the two compounds.
S. aureus biofilms are versatile, in that, they can be composed of varying
components including polysaccharides like PNAG (O’Gara, 2007), surface-associated
adhesins like the MSCRAMMs or other intercellular adhesin proteins like SasG or SasC
(Corrigan, Rigby et al., 2007; Schroeder K, Jularic et al., 2009) and recently, the role for
eDNA released from lysed bacterial cells has also been realized (Rice, Mann et al., 2007).
Each of these components can play different relative roles depending on the strain of
choice and the ever-changing environmental condition. Therefore, observations regarding
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the variability between genetically related strains like 10833 and Newman in their
capacity clump in chelated solutions (Figure 11) and the inherent microscopic
differences between the biofilms produced by strain 10833 within the chelated versus
non-chelated media (Figure 12), prompted the need for an investigation into each of
these components. Figure 13 indicated that 10833 exhibits increased adherence to
catheter tubing within EGTA relative to control, which highlights the phenotypic
variability among strains of S. aureus under various growth conditions such as metal ion
chelation. S. aureus biofilms produced by strains like SA113 and MN8 appear to rely
more heavily on PNAG production. However, 10833 was observed to produce very
minimal amounts of this polysaccharide within EGTA indicating that these biofilms are
formed independent of PNAG production (Figure 14A). The reduction in PNAG
production by EGTA is not completely surprising since observations similar to this were
previously recorded for the CoNS S. epidermidis where EDTA, another chelating agent,
was shown to significantly reduce the amount of polysaccharide production (Ozerdem
Akpolat, Elci et al., 2003).
Although we conducted preliminary studies on a number of S. aureus isolates, we
focused our studies on strains 10833 and Newman. Due to their genetic similarity, we
hypothesized that the contrasting and opposing effect of chelating agents on biofilm
formation in these strains was based on the differential expression of just one or a few
genes. Indeed, we found that biofilm formation by 10833 in the presence of EGTA or
NaCi required expression of the clfB gene (Figure 15). Isogenic deletion of clfB in 10833
strongly repressed biofilm formation and further weakened the phenotype in strain
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Newman in the presence of EGTA but did not affect biofilm formation in the absence of
EGTA (Figure 17A, B). This suggests that, despite a decrease in clfB expression in the
presence of EGTA in Newman, whatever ClfB is present on the surface of S. aureus,
contributes to biofilm formation in these conditions. The finding that biofilm formation is
unaffected by the clfB deletion in TSBG suggests that other biofilm-related factors
contribute to biofilm formation in the absence of EGTA but that ClfB is the major
determinant of biofilms formed in chelated media. Strain USA300 JE2 and two cardiac
device associated isolates- Strains 19, and 24 that were observed to possess increased
biofilms with EGTA and NaCi, lost this phenotype when clfB mutant constructs were
made within these strains (Figure 18B, 19). This reaffirmed our previous finding,
highlighting ClfB as the sole surface-associated proteinaceous MSCRAMM that
facilitates increased biofilms within the chelated media.
Biofilms produced by S. aureus are held together by a mixture of proteinaceous
adhesins along with polysaccharides and eDNA. Because so many factors can contribute
to the formation of a biofilm, the phenotype may be difficult to target pharmacologically,
and agents with antibiofilm activity against certain strains may not inhibit biofilm
formation in other strains. It also suggests that a further analysis of the effect of serum on
biofilm formation as seen in Chapter 3, could potentially reveal the existence of strains
that are able to form biofilms in serum. Strains that were observed to show increased
aggregation and biofilm formation (10833 and USA300 JE2) in the presence of EGTA
were significantly inhibited in this capacity with the introduction of a polyclonal IgG
rabbit α-ClfB antibody (Figures 20, 21A, 21C). This significant finding would support
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the idea of using surface-associated adhesins as potential vaccine candidates. A recent
study conducted by Stranger-Jones et al., in which mice were immunized with each of 19
purified MSCRAMM adhesins including ClfB, ClfA and FnbA and then challenged by
intraperitoneal infection, showed some degree of protection (Stranger-Jones, Bae et al.,
2006).
In sum, S. aureus exhibits significant strain-to-strain variability in its ability to form
a biofilm under different conditions. When Ca2+ is depleted by chelating agents, biofilm
formation is abrogated in some strains, whereas it is retained or even augmented in
others. ClfB has not been implicated in biofilm formation previously, but this study
demonstrates a role for this surface protein in mediating biofilm formation under chelated
/ Ca2+ deplete conditions. Presence of a an EF-hand domain that it can coordinate divalent
cations (Ni Eidhin, Perkins et al., 1998) and a putative protease cleavage SLAVA motif
(McAleese, Walsh et al., 2001) within ClfB suggests regulation of ClfB may occur on
multiple levels involving protein stability and activity. The regulation of the clfB gene
will be discussed further in the next chapter.
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CHAPTER 5
Regulation of Clumping factor B (ClfB) is mediated by calcium (Ca2+)

Introduction
It is estimated between 250,000 – 500,000 infections related to intravenous
catheter use, 1-6 per 1,000 catheter days, occur every year in the U.S. (Crnich and Maki
et al., 2005; Maki, Kluger et al., 2006; Ramos, Reitzel et al., 2010). S. aureus is one of
the most common isolates (20%) and is responsible for a greater associated health-cost
than any other species (Walz, Memtsoudis et al., 2010). Such infections occur, in part,
because S. aureus forms resilient biofilms on the surface of the catheter. Intraluminal
catheter lock solutions (CLS) composed of chemical chelators like trisodium citrate
(NaCi), Ethylenediaminetetraacetic acid (EDTA), and Ethylene glycol-bis(2aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), have been traditionally used to
serve as effective anti-coagulants but also have inhibitory effects against bacterial growth
and biofilm formation (Mermel, Farr et al., 2001; O’Grady, Alexander et al., 2002; Raad,
Costerton et al., 1993; Arakawa, Saito et al., 2000; Raad and Hanna, 2002; Weijmer,
Debets-Ossenkopp et al., 2002). Surprisingly, however, we have identified the prevalence
of S. aureus strains that counter the inhibitory effects of chelators and actually form
stronger biofilms in the presence of these agents. The molecular basis for this
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“antibiofilm resistance” in strains was observed to depend upon the surface-associated
fibrinogen-binding MSCRAMM clumping factor B (ClfB) (Chapter 4).
As described schematically in Figure 23, Clumping factor B is a large 150 kDa
protein that bears a C-terminal LPETG motif which is used to covalently anchor the
MSCRAMM to the cell wall peptidoglycan via a reaction catalyzed by sortase A
(Schneewind, Mihaylova-Petkov et al., 1993). The A or ligand binding domain of this
protein, mediates bacterial adherence to immobilized fibrinogen, blood clots, conditioned
biomaterial ex vivo, and thrombin-damaged heart valves in a rat model of infective
endocarditis (Vaudaux, Francois et al., 1995; McDevitt, Francois et al., 1994; Entenza,
Foster et al., 2000; Francois, Schrenzel et al., 2000; Ni Eidhin, Perkin et al., 1998;
O’Brien, Walsh et al., 2002). The A domain contains a short SLAVA motif, which is
cleaved by the S. aureus metalloprotease- aureolysin (McDevitt D, Francois et al., 1994;
McAleese, Walsh et al., 2001). Furthermore, the A region also contains a non-consensus
abbreviated EF-Hand domain that is known to bind calcium ions (Ca2+) specifically to
promote fibrinogen binding (Ni Eidhin, Perkin et al., 1998). That said, it was rational for
us to hypothesize the following: strains of S. aureus like 10833 that promoted biofilm
formation within chelating agents utilize this domain to facilitate intercellular aggregation
and clumping, which aid in establishing a biofilm. In contrast to ClfA, clfB is expressed
in vitro during exponential growth (McAleese, Walsh et al., 2001). However, the specific
molecular mechanisms that control its expression, stability, and activity, especially within
biofilm formed within chelating agents, remains to be elucidated; as does the molecular
basis for the phenotypic disparity between in EGTA or NaCi between strain pairs such as
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Figure 23. Schematic representation of ClfB. Signal sequence (S), ligand binding
domain (A), serine-aspartate repeat region (SD-Repeat), cell wall spanning domain (W),
and the membrane-anchoring domain (M). The black box at residue 310 is the
abbreviated EF-Hand domain. The shaded blue box is a proline rich region that separates
the A domain from the SD Repeat region. The SLAVA motif spans residues 197 through
201, and the cell wall anchoring LPETG motif spans residues 874 to 878. The aureolysin
cleavage site within the SLAVA motif, between residues Leu198 and Ala199, is shown
(red arrows).
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Newman and 10833.
S. aureus virulence factors including biofilm formation, expression of surfaceassociated and secreted proteins, and quorum sensing is controlled by the major global
regulatory Agr system. The agr locus contains two divergent promoters, P2 and P3,
which encode the RNAII and RNAIII transcripts respectively. RNAIII is the primary
effector molecule of the agr response and is responsible for upregulating extracellular
proteases and exoenzymes including hla (α- toxin) (Morfeldt, Taylor et al., 1995;
Oscarsson, Kanth et al., 2006) and sspA (serine proteinase) (Oscarsson, Tegmark-Wisell
et al. 2006), and downregulating of cell wall associated proteins, such as the fibronectinbinding proteins (FnbA and FnbB) and spa (protein A) (Novick, Ross et al., 1993) during
the post-exponential phase of growth. The Agr system controls the size of the developing
biofilm, and serves as a mechanism of biofilm dispersal, when the bacterial population
reaches a certain density or “quorum” within a confined space.
Proteases are important virulence factors for a variety of microbial pathogens and
may contribute to tissue degradation and resistance to the host defense system. S. aureus
secretes 4 major extracellular proteases: staphylococcal serine protease (V8 protease)
(SspA), a metalloprotease named aureolysin (Aur), a cysteine protease (ScpA)staphopain, and a second cysteine protease (SspB) encoded within the same operon as
SspA (Arvindson, 2000; Chan and Foster, 1998; Hofmann, Schomburg et al., 1993;
Rice, Peralta et al., 2001). Aureolysin is a Ca2+ stabilizing, zinc (Zn2+)-dependent
member of the thermolysin family of Zn2+-dependent metalloproteases. Coordinaton of
the one Zn2+ ion contributes to the catalytic pocket of the protease while binding of three
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Ca2+ helps stabilizes the protease and augments its proteolytic activity. Little is known
about the exact role of aureolysin in the pathogenicity of S. aureus. Recently though,
aureolysin was shown to cleave ClfB at the SLAVA motif (Figure 22), shedding the
molecule into the growth medium thereby explaining the inability of bacteria from
stationary phase to bind to fibrinogen in a ClfB-dependent manner (McAleese, Walsh et
al., 2001).
In eukaryotic cells, study of Ca2+ as a second messenger molecule has long been
documented. An equally important role for this ion has been much harder to demonstrate
in prokaryotes but is now becoming evident. Within prokaryotes, Ca2+ has been
implicated in regulation of various cell processes including cell differentiation and spore
formation in Bacillus subtilis (O’Hara and Hageman, 1990; Fry, Becker-Hapak et al.,
1991), chemotaxis (Tisa, Olivera et al., 1993; Tisa and Adler, 1995; Matsushita, Hirata et
al., 1988) and regulation of cell cycle processes like chromosome segregation and
replication in E. coli (Botello and Nordstrom,1998) and adhesion and aggregation by
dental plaque causing Streptococcus mutans (Rose, Dibdin et al., 1993). More recently,
Ca2+ has also been shown to play a role in biofilm formation and PIA production in P.
aeruginosa and S. epidermidis respectively (Sarkisova, Patrauchan et al., 2005; Ozerdem
Akpolat, Elci et al., 2003; Banin, Brady et al., 2006). The divalent cation stimulates cellcell adhesion and thus promotes aggregation of the organisms adhering to a finite surface,
essential steps towards establishing a successful biofilm. More recently, alternative
means of regulation by Ca2+ have been documented- acting in a primary extracellular
fashion rather than a second messenger. Regulation of these proteins in such a fashion is
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mediated through the presence of a Ca2+-binding EF Hand domains. S. aureus proteins
like ClfA, ClfB and Bap (biofilm-associated protein) bear similar EF-Hand domains and
their innate functional capacity including binding to fibrinogen (ClfA and ClfB) or their
multicellular biofilm formation (Bap), is severely hindered if not abolished completely
when Ca2+ is bound to these sites (O’Connell, Nanavaty et al., 1998; Ni Eidhin, Perkin et
al., 1998, Arrizubieta, Toledo-Arana et al., 2004)
Transcriptional regulation of clfB by major regulators Agr or SarA has only
prevailed with contrasting knowledge. According to previous studies, it has been
accepted that the extracellular surface-associated protein genes including entA, cna, and
clfA are not regulated by agr (Novick, 2003). One study performed in S. aureus
NCTC8325-4 indicated that much more ClfB was present in the agr mutants than in
wildtype cells, suggesting that ClfB expression was negatively regulated by the Agr
system (Frees, Sorensen et al., 2005). In addition, another study performed in S. aureus
Newman suggested that mutation in neither sarA nor agr affected clfB transcription when
measured by lacZ transcriptional fusions (Wolz, McDevitt et al., 1996). The goal of this
study was to elucidate whether a post-translational level of regulation of ClfB- affecting
protein stability and activity, especially during biofilm formation under chelating
conditions occurred thereby augmenting biofilm formation in strains like 10833. Results
from this study revealed ClfB regulation occurred through the independent or synergistic
activities of the metalloprotease aureolysin and Ca2+-binding to the EF Hand domain of
the ClfB protein. This level of regulation shed light on how ClfB exhibited the diametric
biofilm properties by differing strains like 10833 and Newman when cultured within
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chelating agents like EGTA or NaCi.

Results
Agr expression is stronger within Newman than 10833
With the aim of investigating the differential biofilms phenotypes between strain
pairs 10833 and Newman, we explored the role of Agr and its contribution within
chelator based biofilms. The agr locus was shown to downregulate S. aureus adherence
to fibrinogen and agr mutants showed increased adherence to immobilized fibrinogen
and induction of bacterial aggregation (Shenkman B, Rubinstein et al., 2001). We
therefore postulated that there could be a differential level of the Agr activity within these
two strains. RNAIII, the major effector molecule of the agr response, is responsible for
upregulating various extracellular proteases and exoenzymes including hla (α- toxin)
(Morfeldt, Taylor et al., 1995; Oscarsson, Kanth et al., 2006) and sspA (serine proteinase)
(Oscarsson, Tegmark-Wisell et al. 2006). It could therefore inhibit retention of proteins
like ClfB on the surface of the cell or it could directly affect transcription of clfB.
S. aureus produces several membrane-damaging toxins that lyse various types of
host cells. The most prominent examples of single-component toxins include the α-(hla),
β-(hlb), and δ-toxins (hld). The δ-toxin gene (hld) is encoded within the RNAIII effector
molecule. δ-Toxin can lyse a wide variety of mammalian cells including erythrocytes.
Therefore, hemolytic activity on blood agar plates can serve as a measure of the Agr
activity because δ-hemolysin (hla) is encoded within the agr locus. We tested a panel of
strains for hemolytic activity by streaking them on Brucella blood agar (containing
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sheep’s blood) and allowing them to grow at 37 °C for 18 h (Figure 24A). RN450 and
RN450 Δagr serve as our positive and negative controls respectively. RN450 presented
strong hemolytic activity represented by the zone of clearing around the bacterial streak.
Though closely related, we observed Newman to exhibit stronger hemolytic activity than
10833. Hemolytic activity by 10833 was very similar to that displayed by RN450Δagr.
To confirm these results, total RNA was isolated from 10833 and Newman grown
within chelated and non-chelated media and quantitative realtime RT-PCR analysis of the
RNAIII transcript levels, encoded within the agr locus, was determined (Figure 24B).
Under both media conditions tested, Newman displayed greater RNAIII transcript levels
versus that in 10833. This lead us to hypothesize the increased protease activity,
associated with increased expression of Agr, could prevent strains like Newman from
retaining ClfB on the surface and thus explaining the decreased biofilm phenotype of this
strain within chelated media.

Deletion of agr does not restore Newman biofilms within EGTA
Identifying increased expression and hemolytic activity of the agr locus within Newman,
we decided to delete the agr locus from Newman and thereafter assess whether loss of
this locus, and its potential downstream effects, could restore biofilm formation of
Newman within chelated media. Deletion mutation of agr within Newman was generated
by transducing the mutation from the RN450Δagr::tetM strain, utilizing phage 80α. The
resultant transductant colonies (Newman Δagr::tetM) were picked and rescreened on
tetracycline plates. To confirm the loss of the hemolytic activity, contributed by δ-toxin
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Figure 24. Expression and activity of Agr by 10833 and Newman. (A). S. aureus
strains SA113, MN8, RN450, RN450Δagr::tetM, Newman and 10833 were streaked onto
Brucella blood agar plate containing sheep’s blood. A zone of clearing around the
bacterial streak is a positive test for hemolysis. (B) Relative expression of RNAIII was
determined by isolating total RNA from Newman and 10833 grown to late exponential
phase (5 h) within TSBG or TSBG + 12.5 mM EGTA. Quantitative realtime PCR
analysis was performed and the relative fold expression of the RNAIII transcript,
normalized to the 16S rRNA, is shown graphically. **P<0.0001 as determined by
Student’s t-test.
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gene (hld), four transductants (Colonies A-D), along with 10833 and Newman wildtype,
were streaked onto Brucella blood agar (Figure 25A). Compared to our wildtype
Newman strain (positive control) the various isogenic agr mutant transductants relieved
the strength of hemolysis. Compared to 10833 (negative control), the agr mutants
continued to show residual amounts of hemolytic activity. This can be explained knowing
deletion of agr only represses the δ-hemolytic activity; the other hemolytic genes [α(hla), β-(hlb) and γ-(hlgA, hlgB, hlgC) toxins] could contribute to the trace hemolytic
activity observed. Thus, though they do not compare exactly to 10833, there was a
decrease in the amount of hemolysis produced by the NewmanΔagr transductants with
Colony A showing the most significant amount of repression of this phenotype.
To determine whether agr inhibits Newman from forming biofilm within chelated
media, we assayed the newly acquired agr mutant for biofilm formation under chelating
and non-chelating conditions (Figure 25B). Compared to the wildtype, deletion of agr
lead to a decrease in biofilm formation in TSBG. However, NewmanΔagr showed a 13%
increase in biofilm formation within EGTA (P<0.01). Nonetheless, these biofilms within
EGTA were still significantly lower than what has been observed with 10833 biofilms in
the same chelated conditions. In sum, while a direct role for Agr was not determined by
this study, results suggest that the agr locus may play an indirect role in mediating
biofilm formation under these Ca2+ depleted/chelated conditions- possibly through the
increased expression and activity of secreted proteases.
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Figure 25. Deletion of agr restores Newman biofilms minimally. (A) Phage
transductants (Colonies A – D) of NewmanΔagr::tetM were streaked on Brucella blood
agar plates, along with wildtype Newman and 10833, to confirm loss of the agr locus
through depreciated hemolytic activity. Colony A showed the most, visually discernible
decrease within hemolytic activity. (B). Newman Δagr::tetM (Colony A) was tested for
augmented biofilms within chelated media and compared to wildtype Newman and
10833 by diluting overnight cultures of strains in TSBG or TSBG + 12.5 mM EGTA,
added to wells of a 96-well plate and assayed for biofilm formation. The biofilms were
washed for non-adherent bacteria and stained and quantified for any detectable biofilm.
The experiment was performed in biologic triplicate and each triplicate contained four
technical replicates for statistical analysis. * P<0.01 and **P<0.0001 as determined by
Student’s t-test.
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Aureolysin deletion augments Newman biofilms
Early work performed on identifying the regulatory network associated with ClfB
identified a role for the protease aureolysin (McAleese, Walsh et al., 2001). Aureolysin
cleaves ClfB between Ser197 and Leu198 within the SLAVA motif, located within
Region A of the protein, thereby preventing the protein from binding immobilized
fibrinogen (McAleese, Walsh et al., 2001; Perkins, Walsh et al., 2001) (Figure 22).
Additionally, previous observations showing a possible role for agr mediated regulation
of biofilm through increased protease activity provided the necessary leverage to
determine the role aureolysin played in mediating biofilms within chelated media.
Aureolysin is a Zn2+ dependent metalloprotease and is stabilized by three Ca2+ ions. Its
activity would therefore be expected to respond to chelating agents and could therefore
be involved in regulating biofilm formation in the presence of chelators. To test this
hypothesis, we phage transduced the transposon insertion mutation of aur from the
Nebraska Tn Library strain NE163, into wildtype 10833 and Newman and tested for
biofilm formation under chelating and non-chelating conditions (Figure 26).
Deletion of aur from 10833 revealed similar results as the wildtype strain, biofilm
formation being augmented under chelating conditions. If aureolysin was responsible for
cleaving ClfB from the surface of cells then the aureolysin mutant should be rendered
ineffective against biofilm production within strains like 10833 where ClfB is the
predominant proteinaceous adhesin promoting this process. Surprisingly, in contrast with
wildtype Newman where ablated or diminished biofilms were detected, deletion of aur
from this strain reversed the biofilm phenotype under chelating conditions. Deletion of
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Figure 26. Aureolysin deletion mutant fully restores Newman biofilms within
chelated media. The aur transposon insertion mutation was phage transduced from strain
NE163 into 10833 and Newman and tested for biofilm formation with TSBG or TSBG +
12.5mM EGTA or TSBG + 12.5 mM NaCi. Diluted cultures of the wildtype or isogenic
mutant strain were inoculated into wells of a 96-well plate and grown for biofilms.
Safranin stained biofilms (right) were quantified at A415nm (left). Statistical data was
obtained from three biologic replicates; each with four technical replicates. **P<0.0001
as determined by Student’s t-test.
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Newman aur increased biofilm formation significantly within EGTA and NaCi
(P<0.0001); similar to what was observed with 10833 and its isogenic aur mutant. These
results suggest a role for the aureolysin protease playing a role in increased biofilms
within chelated media and potentially cleaving ClfB, within that putative protease
recognition SLAVA motif, preventing ClfB-dependent biofilms within chelated media
from forming. No observable difference between wildtype and the aur mutant of 10833
suggests variable aureolysin activity in this strain versus that in Newman, which could
account for the opposing biofilm phenotypes that exists between the related strains.

Synthesized aureolysin disperses established S. aureus biofilms
If our hypothesis is correct, that aureolysin is responsible for the lack of biofilm
formation in strain Newman under chelating conditions and that the biofilm positive
phenotype in 10833 is due to reduced production of aureolysin, then we should be able to
add aureolysin exogenously to 10833 and to the aur deletion mutants and reduce biofilm
formation in the presence of EGTA. Thus, we next investigated the role aureolysin
played in specifically dispersing S. aureus pre-established biofilms. S. aureus strains
10833, 10833Δaur::Tn, and Newman Δaur::Tn, the only strains that permit biofilm
formation within chelated media, were grown for biofilms within TSBG or added 12.5
mM EGTA. Established biofilms were thereafter washed to remove non-adherent
bacteria, and treated with varying concentrations of recombinant aureolysin synthesized
from S. aureus strain V8-bc10, diluted in deionized water to prevent any added growth,
and allowed to incubate for another 18 h stationarily. The biofilms were observed
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visually and quantified for retention of the pre-established biofilm (Figure 27).
Strain 10833 (Figure 27A) displayed adherent biofilms when grown, in either
TSBG alone or with 12.5 mM EGTA, in the absence of any aureolysin. However,
increasing concentrations of aureolysin promoted dispersion of the retained biofilm
within EGTA. Concentrations ≥5 mM aureolysin prevented any detectable biofilm from
being retained within EGTA (P<0.0001). In contrast, biofilms pre-established within
TSBG continued being retained at all concentrations of the protease tested. This
reinforces the concept that while 10833 biofilms formed in TSBG are likely composed of
various components including exopolysaccharide and other surface-associated
proteinaceous adhesins, biofilms produced within chelated media are largely ClfBdependent. Additionally, this confirmed aureolysin protease cleaving ClfB from the
surface of the cells thereby preventing intercellular aggregation and biofilm retention.
Strains 10833Δaur::Tn (Figure 27B) and Newman Δaur::Tn (Figure 27C) showed
identical trends as wildtype 10833, that is, dispersion of any retained biofilm within
EGTA with ≥5 mM aureolysin. The use of Newman Δaur::Tn was an important control
not only showing the importance of aureolysin in cleaving ClfB from the surface but the
biofilms produced by this isogenic mutant reaffirms the evolving hypothesis that
variability does exist between 10833 and Newman aureolysin.

Newman aureolysin confers the biofilm-negative phenotype on 10833 in EGTA
Thus far we have identified the metalloprotease aureolysin as being responsible
for cleaving ClfB from the surface of cells thereby preventing cells from aggregating and,
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Figure 27. Dispersion of pre-established chelator induced biofilms is mediated by
aureolysin. Biofilms pre-established by S. aureus strains 10883 (A), 10833 Δaur::Tn
(B), and Newman Δaur::Tn (C) within TSBG or TSBG + 12.5 mM EGTA were treated
with varying concentrations (0 – 20 mM) of synthesized aureolysin recombinant protein,
diluted in water, and incubated for 18 h at 37 °C. Dispersed or retained biofilms were
stained with safranin and imaged (right). Quantified assessment of the biofilms was
generated by dissolving the stain in acetic acid and measuring at A415nm (right). Three
biologic replicates, each with four technical replicates was used to generate the statistical
analysis. **P<0.0001 as determined by Student’s t-test.
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A. Strain: 10833 WT

B. Strain: 10833 Δaur::Tn
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C. Strain: Newman Δaur::Tn
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in turn, developing into biofilms. However, the opposing biofilm phenotypes exerted by
10833 and Newman within chelated media; augmented biofilms by 10833 and repressed
or ablated phenotype within Newman, suggested variability between the native
aureolysin activity between 10833 and Newman. Increased activity of the protease within
Newman could prevent biofilm formation of this strain within chelated media. Therefore,
to specifically identify a differing level of activity of this protease between the two strains
we used the IPTG inducible expression vector pCL15 to complement either the 10833 or
the Newman aureolysin gene (aur) into each of the isogenic aur deletion strains and
thereafter test for biofilm formation (Figure 28A).
Biofilm assay of 10833Δaur and NewmanΔaur complemented in trans with the
10833-aureolysin gene formed strong biofilms in EGTA. In contrast, complementation of
the aur deletion mutants with the Newman aureolysin gene not only prevented biofilm
formation within the Newman background but also barred biofilms within strain 10833 in
EGTA. These results suggest that a significant variability exists between the aureolysin
proteins of 10833 and Newman. Newman aureolysin disallowed biofilm formation of
either strain in EGTA, whereas 10833 aureolysin did not.
To confirm these results, we performed aggregation and clumping assays using
these deleted and complemented strains and determined if complementation with
Newman aureolysin would prevent clumping of bacteria when static cultures were grown
in TSBG or added 12.5 mM EGTA (Figure 28B). The top panel of this figure shows
aggregation of the bacteria within the 10833 background. Deletion of aur from 10833
was observed to promote a strong clumping phenotype similar to wildtype within the
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Figure 28. Variability within the aureolysin protease activity between Newman and
10833 affects biofilm formation and aggregation. (A) To highlight the variability that
exists between the native Aur activity between 10833 and Newman, strains were
complemented with either 10833 or Newman aur gene within their respective aur mutant
background and tested for biofilm formation within chelated versus non chelated
conditions. Complementation constructs were induced (I) in the presence of 1 mM IPTG.
Uninduced samples (U) were not supplemented with any IPTG. Statistical analysis was
performed using three independent biologic replicates, each containing four technical
replicates. The arrow highlights the effectiveness of complementation in trans with the
Newman-aur gene. **P<0.0001 as determined by Student’s t-test. (B) Aggregation and
clumping assay was performed to confirm the biofilm phenotype observed in (A).
Wildtype, aur mutant and aur complementation strains of 10833 and Newman were
grown in test tubes with either TSBG or TSBG + 12.5 mM EGTA and allowed to
incubate stationarily for 18 h at 37 °C. The tubes were vortexed briefly and then imaged.
Complemented strains were induced with the addition of 1mM IPTG. The red circle
highlights a clumped phenotype observed within the volume of the liquid.
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chelated condition. Clumping was also observed when 10833 aur mutants were
complemented with its native copy of aur. However, complementation with Newman aur
prevented any aggregation of the bacteria. Aggregation assays with the Newman
background (bottom panel, Figure 28B) revealed clumping of bacteria within the aur
mutant and loss of this phenotype when the aur mutant of Newman was complemented
with the Newman-aur gene. Taken together, we confirmed the variability in the
aureolysin activity between 10833 and Newman- Newman possess the aureolysin
protease in a fully active and functional form that is sufficient to cleave ClfB from 10833
preventing this strain from inducing biofilms within chelated media.

10833 does not encode functional aureolysin
To confirm the phenotypic effects of Newman aureolysin we sequenced the aur
gene from 10833 and Newman and compared these sequence results to the aur published
sequence from strain Newman (Baba, Bae et al., 2008) (Figure 29). Two sets of primers
were designed to provide full coverage of the aur gene. Sequence results from Newman
aur revealed 100% identity and similarity to the published aureolysin sequence. Analysis
of 10833 aur showed 100% identity to the region upstream of the protein coding open
reading frame. However, 10833 aur protein coding sequence (1493 bp) contained 3
deletion mutations relative to Newman aur (1497 bp). The nucleotides at positions 565,
604, and 671 were absent in the 10833 aur sequence and there was one substitution
mutation at nucleotide 623. Deletion of thymine 565 resulted in a frame shift of the
protein coding sequence resulting in an inframe TAG (DNA) or UAG (RNA) that
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Figure 29. Sequence analysis of the 10833 aur gene reveals insertion of a premature
stop codon. The aureolysin (aur) gene was amplified from 10833 and Newman genomic
DNA sequenced and compared to the published protein coding aur sequence from
Newman (Published). The green and red box highlights identical start and stop codons
across all three sequences. The blue boxes highlight the 4-nucleotide polymorphismsthree deletions (at nucleotides 565, 604, and 671) and one substitution (at nucleotide 623)
that exists between 10833 and the sequenced or published Newman aur. 100% identify
was observed between the Newman aur sequenced and the published Newman aur
sequence. The dashed lines signify the intermediate sequence between all three that were
100% identical. The red star identifies the deleted nucleotide (thymine 565) from 10833
that causes a frame shift in the open reading frame resulting in the insertion of a
premature stop codon.
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encodes for a stop codon. Thus, the 10833 aur protein coding sequence would not be
expected to encode a functional aureolysin protein. These results were highly significant
and confirmed previously observed phenotypic data showing 10833 aureolysin having
lower protease activity versus that from Newman.

EF-Hand domain and calcium mediated regulation at the level of ClfB protein
activity
While aureolysin may account for the differences between strains in their capacity
to form biofilms within chelated media, we also aimed to investigate the role of the helixloop EF-Hand domain that has been characterized to bind Ca2+ very specifically.
Several lines of evidence have implicated Ca2+ in the regulation of various bacterial
processes including chemotaxis, cell differentiation, and adherence and aggregation
(O’Hara and Hageman, 1990; Fry, Becker-Hapak et al., 1991; Tisa, Olivera et al., 1993;
Tisa and Adler, 1995; Matsushita, Hirata et al., 1988; Rose, Dibdin et al., 1993). These
domains, within S. aureus, have been identified to regulate processes like intercellular
aggregation, adherence to host proteins, and biofilm formation (O’Connell, Nanavaty et
al., 1998; Arrizubieta, Toledo-Arana et al., 2004). Clumping factor B has an EF-hand
domain, suggesting that it can coordinate divalent cations, and its autoaggregative
activity and capacity to bind fibrinogen is inhibited by Ca2+ and Mn2+ (Ni Eidhin, Perkin
et al., 1998). Therefore, an additional level of regulation, affecting protein activity, would
be suspected.
To assess the role for divalent cations like Ca2+ or Mn2+ in dispersing biofilms we
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performed dispersion assays where 10833 biofilms were pre-established in 12.5 mM
EGTA, and once established, were treated with varying concentrations of metallic cations
including Ca2+, Magnesium (Mg2+), and Manganese (Mn2+) and tested for biofilm
retention (Figure 30A). The ions were diluted in deionized water to prevent any added
growth of the bacteria thus highlighting the role for the divalent cations, alone, on biofilm
dispersion or retention. Deionized water served as the positive control and prevented any
loss of the biofilm. However, high concentrations of Ca2+ prevented biofilm retention
with 3.125 mM Ca2+ being the minimum biofilm eradication concentration (MBEC)
(P<0.0001). Neither Mg2+ nor Mn2+ adversely affected the phenotype; biofilms treated
with these ions were fully retained similar to the water control.
While the effect of Ca2+ could potentially be attributed to an increase in
aureolysin activity there is also the possibility that this effect is due to Ca2+ binding to the
EF-Hand domain of ClfB, preventing the bacteria from aggregating and being retained as
a biofilm. To determine whether the effect of Ca2+ was mediated through aureolysin or
through the EF-Hand domain of ClfB, we tested similar dispersion/retention biofilm
assays using biofilms pre-established by 10833Δaur::Tn and Newman Δaur::Tn within
EGTA and then treated with increasing concentrations of Ca2+ (Figure 30B). As
previously observed in Figure 30A, ≥3.125 mM Ca2+ prevented 10833 wildtype biofilms
in EGTA from being retained. However, both aur mutants were observed to prevent
biofilm formation at ≥6.25 mM Ca2+ (P<0.0001). This would suggest, while the effect of
aureolysin on ClfB stability may play a more predominant role in preventing the protein
from being retained on the bacterial surface, to promote aggregation and biofilm
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Figure 30. High concentrations of Ca2+ ions disperse pre-established S. aureus
biofilms. (A) To assess the relative contribution divalent cations and their effect through
the ClfB EF-Hand domain, biofilms were pre-established by 10833 within 12.5 mM
EGTA. The biofilms were thereafter treated with varying concentrations (12.5 mM – 0
mM) of divalent cations including Mg2+, Mn2+ and Ca2+ or deionized water. The plates
were incubated once again for 18 h at 37 °C and then washed for non-adherent or
dispersed bacteria, stained (right) and quantified at A415nm. (left). (B) The Ca2+ mediated
effect on the ClfB EF-Hand domains, independent of aureolysin, was determined by preestablishing biofilms by 10833 wildtype or 10833 and Newman aur mutants in 12.5 mM
EGTA which were thereafter treated with varying concentrations (25 mM – 0 mM) of
Ca2+. The experiments were performed in biologic triplicate with each condition being
tested in technical quadruplets. **P<0.0001 as determined by Student’s t-test.

156

A. Strain: 10833 WT

B.
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formation, inhibitory effects of Ca2+ binding to the EF-Hand domain is stimulated at
higher concentrations of Ca2+ and can function independent of aureolysin. These results
present a novel post-translational regulatory network associated with ClfB-dependent
biofilms, where Ca2+ binding to the EF-Hand domain affects ClfB activity and its
capacity to form biofilms within chelated media.

Discussion
Biofilm formation by S. aureus is an important virulence mechanism associated
with this species, and as a result, S. aureus is a leading cause of catheter-related BSIs, a
significant and growing worldwide concern. The use of catheter lock solutions containing
chemical chelators like NaCi, EDTA, and EGTA have been shown to provide an antithrombotic function, as well as, an antimicrobial and antibiofilm effect (Arakawa, Saito
et al., 2000; Raad and Hanna, 2002; Weijmer, Debets-Ossenkopp et al., 2002). However,
we have shown previously, that a subgroup of strains including 10833, a close relative of
sequenced strain Newman, grown within such chelating agents, surprisingly, augment
biofilms. This mechanism of increased biofilm formation was promoted through the use
of a specific MSCRAMM protein- clumping factor B (ClfB). The goal of this study was
to chracterize the regulatory mechanism associated with this protein in aiding 10833
biofilms within chelated media and to determine the basis for the different phenotype
observed in Newman.
ClfB is large surface-associated protein, which, in vivo, binds fibrinogen as its
native ligand. However, we have shown ClfB to promote intercellular aggregation i.e.
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clumping between bacteria, a phenotype that precedes the development of robust biofilms
and this occurs in the absence of fibrinogen. As with any developmental process, biofilm
formation is tightly regulated via the coordinated and sequential activities of SarA and
Agr. Expression of SarA is dependent upon growth phase, with its greatest expression
observed during the late exponential growth phase. Thus, it can regulate virulence
determinants in a temporal manner; upregulating surface-associated proteins involved in
initial colonization and biofilm formation like the fibronectin-binding proteins (FnbA and
FnbB) and downregulating expression of extracellular proteases and exoenzymes
(Karlsson and Arvidson, 2002; Chan and Foster, 1998). Mutants with this locus have
been usually identified with lower levels of biofilms (Beenken, Blevins et al., 2003). Agr,
on the other hand, is usually identified with quorum sensing and bacterial
communication, is also associated with the late stages of biofilm development i.e. biofilm
dispersal. This is brought about through the decreased expression of surface proteins
(Novick, Ross et al., 1993) and increased expression of secreted proteases and
exoenzymes (Morfeldt, Taylor et al., 1995; Oscarsson, Kanth et al., 2006; Oscarsson,
Tegmark-Wisell et al. 2006). Our findings that Agr activity was elevated in Newman but
low in 10833, and that deletion of agr in Newman augmented biofilm formation in
EGTA, suggested a role for Agr as a negative regulator of biofilm formation in EGTA,
although whether this effect was direct, through repression of clfB gene expression, or
indirect, possibly through increase protease production was not determined in this study.
Previous work accomplished by McAlesse and colleagues identified a secreted
metalloprotease- aureolysin (aur) to cleave ClfB resulting in decreased binding to
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fibrinogen (McAleese, Walsh et al., 2001). This suggested the possibility of a posttranslational means of regulating this protein. Our hypothesis was confirmed when we
deleted aur from Newman, which restored biofilm formation of the strain similar to that
observed with 10833 (Figure 26). A similar deletion with 10833 did not affect biofilm
formation within EGTA. This supported the likelihood that aureolysin cleaves ClfB from
the surface of the cell thereby preventing Newman biofilms in EGTA or NaCi. Thus,
deletion of this gene from strains like 10833, which already augment biofilms within
chelated media, would remain unaffected. Addition of recombinant aureolysin protease,
exogenously to pre-established biofilms within EGTA using the aur mutants confirmed
this hypothesis. Biofilms pre-established by 10833 and Newman aur mutants were
successfully dispersed with high concentrations of aureolysin (Figure 27), thus
confirming a role of the aureolysin protease specifically cleaving ClfB and implicating a
novel post-translation regulatory mechanism associated with strains that displayed
increased biofilms within chelating agents.
While identifying aureolysin as the protease that cleaves ClfB from the surface of
strains that promote ClfB-dependent biofilms, we had yet to answer the paramount
question of how related strains Newman and 10833 exhibit opposing biofilm phenotypes
within chelating agents. Hypothesizing a variable level of aureolysin activity between
10833 and Newman we constructed complementation aur mutants using Newman or
10833’s copy of the gene, and transformed these constructs into the 10833 or Newman
aur deletion mutants. Biofilm and clumping assays revealed strains that were
complemented with Newman aur prevented biofilm formation and aggregation of both
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10833 and Newman aur mutants. In contrast, complementation with 10833 aur did not
affect biofilm formation or clumping and aggregation in either 10833 or Newman aur
mutants (Figure 28A, B). These findings were better understood during sequence
analysis of the 10833 and Newman aur gene. While only four nucleotide polymorphisms
were observed with the 10833 aur gene, the deletion of thymine nucleotide at position
565 brought about a frame shift inserting a premature stop codon (Figure 29). Thus,
while strain Newman generated a functional protease, strain 10833 did not. Therefore, the
genotypic analysis provided the appropriate rationale behind Newman aur
complementation preventing biofilm formation and clumping while complementation
with 10833 aur did not.
The role of aureolysin as a major regulator of ClfB decisively explains the
variability that occurs between strains like 10833 and Newman and their differential
biofilm phenotype within chelated media. Chelators like EGTA are specific for Ca2+
cations. Dispersal of pre-established 10833 biofilms within EGTA within increasing
concentrations of Ca2+ suggested an additionally level of ClfB regulation- at the level of
protein activity. EF-Hand domains in S. aureus proteins like Bap have been observed to
bind Ca2+ and prevent aggregation and biofilm formation (Arrizubieta, Toledo-Arana et
al., 2004). Similar domains with ClfB suggested a role for Ca2+ mediated regulation of
biofilm formation. Dispersion of biofilms produced by strains that were deleted for aur
with high concentrations of Ca2+ confirmed this hypothesis. This suggested an added
level of regulation whereby, binding of Ca2+ to these helix-loop domains destabilizes the
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ClfB protein and thus prevents intercellular aggregation and biofilm formation and
retention.
Virulence properties of prokaryotes mediated through Ca2+ is an area of research
that is still in its infancy. This chapter has highlight a novel pair of regulatory networks
associated with the variable biofilm phenotype associated with strains like 10833 and
Newman when cultured with chelators like EGTA or NaCi. Understanding that these
biofilms are promoted using the sole surface-associated MSCRAMM ClfB, we have
shown that the decreased retention of the protein on surface of strains like Newman is
mediated by the protease aureolysin. The discrepancy between the biofilm phenotypes is
explained knowing that while Newman encodes a functional aureolysin protease which
cleaves ClfB off the surface of the cell, 10833 does not. Thus wildtype and aur mutants
of 10833 continue to promote strong biofilms within chelated media. Finally, the role for
Ca2+ binding to the EF-Hand domains affecting ClfB activity i.e. its capacity to aggregate
and thus promote biofilms, was a secondary level of regulation identified and this level of
regulation was observed to in concert or independent of aureolysin.
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CHAPTER 6
Conclusions and Future Perspectives
Bacterial nosocomial infections have become more prevalent in recent years with
the increased use of prosthetic biomedical implants. Chronic infection of a prosthetic
implant can serve as a septic focus for bacteremia, which can then lead to metastatic or
disseminated infections, sepsis, and death, particularly in immunocompromised patients
(Christensen, Baldassarri et al., 1994; Gristina, 1987). Staphylococcus aureus is a leading
cause of implant-associated infections. While it is has a commensal relationship with
close to half of healthy individuals, it is opportunistic in nature, and can cause a broad
range of infections from purulent self-limiting skin infections to more severe, potentially
fatal conditions including infective endocarditis and catheter-related BSIs. Colonization
of implanted medical devices including catheters occurs when S. aureus forms tenacious
biofilms, a consortium of sessile cells that tightly adhere to the implant surface and each
other. Once a biofilm has been established it can be very difficult to treat clinically since
the bacteria on the interior of the biofilm are well protected from the host immune
response as well as antibiotic agents (Hoyle and Costerton, 1991). The major aim of this
work was to investigate the effects that compounds to which S. aureus would be exposed
during infection, have on its capacity to form a biofilm. More specifically, the project
elucidates the effects of serum, and thereafter, chelating agents that comprise catheter
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lock solutions on biofilm formation by S. aureus.

Serum-mediated inhibition of Staphylococcus aureus biofilm formation
S. aureus is an exceptionally adaptable organism and responds rapidly to changes
in its environment by modulating the expression of appropriate genes. This flexibility in
bacterial gene expression permits survival in rapidly changing environments and
conditions. Sudden shifts in temperature and osmolarity, mechanical stimulation, carbon
and metal ion availability are some noteworthy environmental conditions which can
induce global changes in S. aureus gene expression that initiate the switch to a sessile
biofilm mode of growth. An important environmental factor to which S. aureus is
exposed during certain types of infections is blood but the effects of blood on biofilm
formation have not been well defined.
The acellular component of blood following removal of clotting factors is serum.
Pre-coating polystyrene with serum is frequently used as a method to stimulate biofilm
formation. The effect of pre-coating with serum is due to the deposition of extracellular
matrix components onto the polystyrene, which are then recognized by MSCRAMMs.
We hypothesized that if serum were included with the culture medium rather than
removed prior to culture, that it would induce biofilm formation. Surprisingly, when the
concentration of human or fetal bovine serum was 10% or more, planktonic growth was
supported but the serum was a potent inhibitor of biofilm formation. Thompson et al.
have since confirmed these results when they observed S. aureus biofilms were promoted
only in the presence of ≤5% serum; such biofilms were dependent on the S. aureus
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secreted extracellular adherence protein (Eap) (Thompson, Abraham et al., 2010). We
found that the inhibitory serum component had a molecular weight less than 3,000 Da.
Precedence for the role of larger molecular weight host serum components including
lactoferrin, apo-transferrin, and albumin that effectively inhibit S. aureus adherence to
polyurethane surfaces and biofilm formation has been well established (Ardehali, Shi et
al., 2002; Ardehali, Shi et al., 2003; Singh, Parsek et al., 2002; Hammond, Dertien et al.,
2008); however, a role for a small molecular weight component/s has never been
established. Furthermore, the inhibitory LMWF component was protease-resistant and
heat stable. We therefore hypothesize that the LMWF component could be a
carbohydrate, a small, heat-stable protein such as an antimicrobial peptide, a nucleic acid
fraction, or a cellular metabolite. Future experiments could determine whether the
compound is a carbohydrate by treating this fraction of serum using sodium
metaperiodate, which oxidizes polysaccharides. To gain some perspective on the role of
AMPs or other low molecular weight heat stable proteins, we could perform SDS PAGE
analysis on untreated versus heat inactivated fractions. Heating should destroy a large
number of proteins however those that continue to remain on the gel could be isolated
and analyzed by mass spectrometry.
We hypothesize, because serum inhibits biofilm formation and yet S. aureus
elaborates biofilms during catheter-related infections that biofilm formation in vivo may
be “selected for” rather than “induced” at the level of transcription by serum. It is
possible that there is a stochastic component to the expression of biofilm-related genes
and that some cells reflect a planktonic gene expression profile, while others, express a
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biofilm mode of growth. Alternatively, a sub-population may encounter different “microenvironmental conditions” leading to the expression of biofilm-related genes. In either
case, we hypothesize that blood components induce the planktonic mode of growth in
vivo to maximize its growth potential in a nutrient-rich environment, but advantages of in
vivo planktonic survival are outweighed by the numerous disadvantages including
exposure to antimicrobials and easier access by host immune defenses. Thus, the few
bacteria that happen to adhere to the device would have a selective advantage over the
planktonic population.
The variability between the transcript levels of genes associated with biofilm
formation or regulation between distinct strains SA113 and Newman in the presence of
the serum component suggests that the response to serum varies between strains. Thus we
can also postulate a strain-based variability to biofilm formation in vivo. With the large
degree of genetic variability that exists between strains it is possible that there are some
strains of S. aureus like 10833 that could be better suited for biofilm formation versus
strains SA113 or Newman. In vivo such strains may ‘sense’ themselves in an
environment where a biofilm mode of growth would be preferred.
Whichever the case, these results have suggested serum-mediated inhibition of
biofilm formation may represent a previously uncharacterized aspect of host innate
immunity and provide a novel outlook into host immunity against the expression of a key
S. aureus virulence factor: the ability to establish a resistant biofilm.
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Chelator based catheter lock solutions augment biofilm formation in a subset of S.
aureus strains in a ClfB-dependent fashion
Catheter-related BSIs are a significant iatrogenic complication associated with the
use of implanted intravascular devices, and incidence increases proportionally with the
length of time that the catheter is left in place. To combat the burgeoning numbers of
catheter-related BSIs, metal ion chelators like NaCi, EGTA and EDTA are frequently
chosen to lock intravenous catheters. While serving a critical anti-thrombotic function,
these chemical compounds additionally provide added antimicrobial and antibiofilm
properties (Banin, Brady et al., 2006; Shanks, Sargent et al., 2006). With the availability
of these improved solutions, there has been a significant decrease in catheter-related
bacteremia within patients (Weijmer, van den Dorpel et al., 2005). Nonetheless, catheterrelated infections still occur, suggesting that bacteria continue to form biofilms even in
the presence of antibiofilm CLS. In contrast to our original hypothesis that CLS had
uniform antibiofilm properties across all strains of S. aureus, we observed this to be true
to only a certain number of strains including SA113 and Newman and 5 out of 27 clinical
isolates. Observing a striking increase in biofilms within 10833, genetically related to
Newman, and others including USA300 JE2 and 8 out of 27 clinical isolates, we
reasoned, similar to our discussion above, strains of S. aureus differ in their capacity to
form biofilms within CLS and this variability is directly related to the strains’ capacity to
form varied types of biofilms, some which are more resistant or tolerant to the antibiofilm
chelators, while others that are specifically targeted by these compounds. We
hypothesized that S. aureus could become resistant or that certain strains may be innately
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resistant to the antibiofilm effects of chelating agents, countering their inhibitory effects,
thus exacerbating the problem of biofilm-associated infections. In the strains tested, we
found that resistance to the antibiofilm effects of CLS was due to expression and
retention of a surface-associated S. aureus adhesin ClfB.
S. aureus exhibits significant strain-to-strain variability in its ability to form a
biofilm under different conditions. Figure 31 describes schematically, a simplified model
of what we believe to occur in vivo during S. aureus colonization and biofilm formation
on catheter surfaces. Pharmaceutically available CLS such as Citra-Lock ™, Dura-LockC ™, and Loxxit ™, composed solely of the chelating agents like NaCi are advertised to
target established biofilms and promote their dispersal (top). At sub-inhibitory
concentrations, the antibiofilm properties of chelators, at least in part, would seem to be
mediated through repressed polysaccharide (PNAG) expression and production.
Therefore, we believe strains like SA113 that rely more heavily on polysaccharides
within their biofilms (Cramton, Gerke et al., 1999), are potentially more susceptible to
the antimicrobial and antibiofilm effects of CLS. However, certain strains rely more
heavily on proteinaceous adhesins rather than polysaccharides for biofilm formation
(Corrigan, Rigby et al., 2007; O'Neill, Pozzi et al., 2008; Hennig, Nyunt Wai et al.,
2007). Strains like 10833 and USA300 JE2, among others, when cultured with chelating
agents, retain the ability to form a biofilm through the coordinated increased expression
and retention of surface-associated ClfB. Once anchored to the bacterial cell surface, the
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Figure 31. Schematic for chelator-based induction of ClfB-dependent S. aureus
biofilms. S. aureus biofilms can be composed for varying components including an
exopolysaccharide (PNAG), proteinaceous adhesins (MSCRAMMs, intercellular adhesin
proteins like SasG, SasC, Bap) and eDNA. Each of these components play mutually
exclusive roles in promoting biofilm formation depending on the nature of the strain and
the changing environmental conditions. (Top) Strains like SA113 rely primarily on
exopolysaccharides like PNAG to facilitate an adherent biofilm phenotype. The addition
of chelators, at least in part, represses PNAG expression and production and thus targets
biofilms to become dislodged. (Bottom) In contrast, strains like 10833, USA300 JE2, VF
Strains #19, and #24, rely on the surface-associated MSCRAMM ClfB, which actually
functions more efficiently when calcium is chelated. Thus, chelators stimulate biofilm
formation especially when proteinaceous adhesins like ClfB are the major component.
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protein promotes intercellular aggregation, resulting in a clumped phenotype, which
progresses towards establishing a biofilm.
Table 4. summarizes our overall results from chapters 3 and 4. Identifying ClfB
as a protein determinant promoting increased biofilm formation in some strains we next
sought to answer two questions: first, “what is the role of ClfB in biofilms formed under
chelating versus non-chelating conditions?” and second, “why do strains 10833 and
Newman differ so dramatically in their response to the chelating agents?”
In response to the first question, we hypothesize from the results of our study, that, under
non-chelating conditions, S. aureus strains such as Newman and 10833 form biofilms that
do not require ClfB. Instead, these biofilms may depend upon different surface proteins,
polysaccharides and/or possibly eDNA. However when these bacteria are grown under
chelating conditions, 10833 and Newman depend upon expression and activity of ClfB.
Chromosomal and insertional inactivation of clfB confirmed that biofilms formed in the
presence of EGTA or NaCi require ClfB, however ClB is expendable for biofilm
formation when the strains are grown under non-chelating conditions. We also
hypothesize, based on our results that the reason for this dependence is that chelators
interfere with other biofilm mediators such as other surface adhesins and polysaccharide
either at the level of transcription or possibly by interfering with surface expression or
even charge. However, ClfB was actually activated, rather than inhibited by chelating
conditions. We found that calcium led to the dispersal of biofilms that had been preestablished in EGTA. This was presumably because calcium inactivated the EF-hand
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Table 4. Biofilm formation by Newman and 10833 under chelating versus non-chelating
conditions

Strain

- Chelator (TSBG) + Chelator (EGTA / NaCi)

Newman

++

+/-

Newman ΔclfB::erm

++

-

Newman Δaur::Tn

++

+++

10833

++

+++

10833 ΔclfB::erm

++

-

10833 Δaur::Tn

++

+++

Biofilm formation scores shown indicate (+++),very strong biofilms; (+/-), diminished
biofilms; (-), no biofilms detected
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domain while calcium removal by EGTA activated the autoaggregative capacity of the
EF-hand domain.
In answer to the second question regarding the difference between strains 10833
and Newman; this variability between the two strains occurs as a result of the effects of
the aureolysin protease. ClfB would presumably be active and contribute to biofilm
formation in both strains, however, in strain Newman, aureolysin prevents this; likely
through cleavage of ClfB from the bacterial cell surface. Therefore, we hypothesize, that
this major mediator of chelator-grown biofilms is removed by aureolysin in strain
Newman and no biofilm is able to form. In contrast, due to a mutation within the gene,
aureolysin is not produced in strain 10833 and the ClfB accumulates on the cell surface
and is highly active under chelating conditions.
Thus ClfB activity is regulated in two ways. Its aggregative activity is turned on
in the absence of calcium but aureolysin can destroy this activity. Figure 32 better
elucidates this schematically. Knowledge that ClfB regulation occurs through two
independent and/or synergistic post-translational networks affecting protein activity and
protein stability can be used as vital information in generating effective therapeutics.
Conjugative therapeutics- combining the anticoagulant properties of chelating agents in
concert with superior proteases like aureolysin, would be ideal, and could be used to
promote disintegration and thereafter prevention of biofilm formation; however, the
enzymatic activity of secreted S. aureus proteases in vivo would have detrimental effects
within the host. Aureolysin degrades antibodies and possibly other host immune
effectors. Recently S. aureus proteases- staphopains (SspA and SspB) were shown to
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Figure 32. Regulatory networks of Clumping factor B during biofilm formation.
Shown is a schematic representation of the ClfB protein identifying the signal sequence
(S), ligand binding domain (A), the long serine-aspartate repeat region (SD-Repeat), cell
wall spanning domain (W), and the membrane anchoring domain (M). The black box at
residue 310 is the abbreviated EF-Hand domain and the shaded blue box is a proline rich
region that separates the A domain from the SD Repeat region. The SLAVA motif spans
residues 197 through 201, and the cell wall anchoring LPETG motif spans residues 874
to 878. Post-translational regulation of ClfB occurs via the independent or synergistic
activities of aureolysin and Ca2+ ions binding to the EF-Hand domain. High
concentrations of Ca2+ ions binding to the EF-Hand affect ClfB activity and thus prevent
aggregation and intercellular adhesion. The metalloprotease aureolysin, on the other
hand, affects ClfB activity. The proteases cleaves ClfB at the SLAVA motif within the A
domain, between residues Leu198 and Ala199 (red arrows), preventing aggregation and
biofilm formation.
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promote degradation of host fibrinogen and collagen, and suggest an involvement of
staphopains in the clotting impairment and tissue destruction caused by staphylococcal
infection (Ohbayashi, Irie et al., 2011). Our studies, while identifying a proteinaceous
adhesin that plays a predominant role in biofilm formation and possibly in bacterial
resistance to CLS, were limited to two lab strains and eight cardiac device-associated
isolates. The clinical gravity of this novel phenotype would suggest it be prudent to gain a
better perspective of the prevalence of the novel phenomenon within catheter-related
bacteremia isolates. Genetic and phenotypic polymorphisms observed with related strains
like 10833 and Newman would suggest an even wider spread among clinical strains S.
aureus. Nonetheless, it would be interesting to compare the aur sequences from the eight
cardiac isolates that demonstrated increased biofilm formation within EGTA and NaCi
and compare them to the five that were repressed for the phenotype.
This research brings to light data regarding strains of S. aureus, in vivo,
encountering a variety of environmental signals that could inhibit or augment the capacity
to form biofilms. We highlight the role for a novel small molecular weight host derived
serum component that successfully prevents biofilm formation. S. aureus being one of the
leading causes of catheter-related BSIs, subinhibitory levels of catheter lock solutions,
contrary to their advertized antimicrobial and antibiofilm properties, may augment
biofilm formation within a subset of S. aureus strains and this phenotype is promoted by
the surface-associated MSCRAMM- ClfB. This significant finding validates and further
emphasizes the clinical burden and downstream hematogenous manifestations S. aureus
catheter-related infections bear. The scientific community is highly interested in the
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enzymatic degradation of bacterial biofilms, as biofilm formation is a cause of many
medical, industrial and environmental problems (Chaignon, Sadovskaya et al., 2007).
Therefore, biological or chemical agents that could disintegrate the biofilm, releasing the
bacteria into the environment, would allow antibiotics and host immune defense to
eliminate the infection with improved efficiency (Chaignon, Sadovskaya et al., 2007).
Clinicians and investigators have found eradication of S. aureus colonization and
infection a daunting task. Nevertheless, the more knowledge gained from studies as such
adds to the wealth of information in hopes of identifying the ‘magic bullet’ that could
prevent staphylococcal biofilm-related infections.
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